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Abstract 
Oxysterol-binding protein (OSBP) is the founding member of a conserved protein family 
found among eukaryotes that functions as a lipid transporter between the ER and Golgi. OSBP is 
ubiquitously expressed in all tissues and is an essential host protein in the viral replication of many 
public health menaces, especially the Enteroviruses. Over the past decade, many broad-spectrum 
anti-viral small molecules have been identified as OSBP inhibitors. The anti-cancer and anti-viral 
natural product, OSW-1, is of interest due to its high affinity for OSBP and its ability to cause 
proteasomal degradation of OSBP. The work outlined in this dissertation details the unique ability 
of the OSW-1 compound to induce persistent OSBP repression in cells through multiple days 
without affecting cell viability. Even in the absence of the OSW-1 compound, the reduced OSBP 
levels confers a prophylactic anti-viral activity against clinical isolates of Enterovirus viruses. This 
long-term reduction is specific for OSBP in the proteasome, and reduction occurs through an 
unknown mechanism that does not involve OSBP proteolysis or transcriptional repression. Of the 
known OSBP small molecule inhibitors with anti-viral activity, only OSW-1 triggered the long-
term repression of OSBP. The OSBP inhibitor compound T-00127-HEV2 was the only compound 
tested able to protect OSBP levels from the OSW-1-induced repression of the protein. Of the OSBP 
inhibitor compounds, only the OSW-1 compound was able to induce the prophylactic anti-viral 
response against two clinical isolates of Enterovirus viruses. The results produced will be 
beneficial in future research that seeks to define OSBP cellular regulation, especially upon OSW-
1 treatment, and to potentially develop prophylactic anti-viral therapeutics through targeting 
OSBP.      
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Chapter 1: Introduction to the Oxysterol-binding Proteins 
1.1 Overview 
Oxysterol-binding protein (OSBP) and OSBP-related proteins (ORPs) are a highly 
conserved family of proteins found in almost all eukaryotes spanning from yeast to humans(1, 2). 
This family of proteins contains a conserved ligand binding domain with the function of binding 
various forms of sterols and phospholipids (1–4). Despite the conserved domains and overlapping 
function, each member of the family seems to have its own role within the cell that appears to be 
involved with membrane lipid homeostasis(2, 5). With these specific roles, each family member 
has been implicated in various forms of cancer as well as other lipid based human diseases(2). The 
true roles that each member of the family plays within the cell is not fully known and the regulation 
of the proteins is unknown. This chapter will outline the basic structure of OSBP/ORPs and their 
specific cellular binding ligands and the known biological role of each family member. OSBP and 
its closest homolog ORP4 will be preferentially highlighted due to their focus in this dissertation. 
This chapter will look at their clinical relevance and the various small molecule ligands that each 
bind while briefly addressing some of the cellular effects that these molecules induce. 
1.2 Oxysterols as ligands for the OSBP/ORPs 
Oxysterols are 27-carbon oxidized forms of cholesterol that are generated through the 
cholesterol biosynthetic pathway and are involved in multiple activities in the body(6, 7). 
Numerous oxysterols are generated by the ER or mitochondria of hepatic cells by cytochrome 
P450 enzymes, in vivo, and also through food processing during cholesterol autoxidation(6, 7) 
(Figure 1). Once produced, these oxysterols serve as major signaling molecules with a variety of 
functions such as development, differentiation, immune functions, apoptosis, etc.(6, 7) (Figure 
2 
2). Like any other cellular signaling molecule, there are specific receptors for oxysterols, one of 






Figure 1: Fates of Cholesterol when processed by CYP450’s. When cholesterol is processed by 
various CYP450 enzymes or oxidation, a variety of oxysterols are produced that contain very 







Table 1: List of oxysterol receptors and the various functions. Table adapted from Olkkonen et al. 
2012. 
Receptor (or rec. Family) Function 
LXRα, LXRβ Transcriptional regulation of cholesterol adsorption and 
cellular efflux, cholesterol and bile acid synthesis, 
neutral lipid secretion into bile, inflammation and 
immune response 
OSBP/ORPs Regulation of lipid homeostasis, vesicle transport and 
cell signaling 
Insig Regulation of SREBP maturation: cholesterol and fatty 
acid biosynthesis and LDL receptor expression 
StarD5 Cellular cholesterol metabolism and transport; up-
regulated upon ER stress 
NPC1 Egress of endocytosed cholesterol out of late endocytic 
compartments 
RORα, RORγ Transcriptional regulation of genes involved in 
development, metabolism, and immunity 
EB12/GRP183 Control of B-cell migration 
Smoothened Hedgehog signaling 
Figure 2: Cellular signaling of oxysterols. Cholesterol is processed into various 
oxysterols and these oxysterols have cellular signaling for developmental processes, 
differentiation abilities, and transcriptional control. They also have inflammation, 
immunity and apoptotic abilities alongside normal metabolic processes of sterols. 
4 
OSBP/ORPs functions are thought to be sterol sensing molecules and the binding of 
oxysterols over cholesterol leads to sterol transport that helps maintain lipid homeostasis of various 
membranes as well as specific signaling events based on the ligand(3, 4, 6, 8, 9). The sensing 
ability of OSBP/ORPs is due to their ability to complex cholesterol and oxysterols(10–17) as well 
as various phosphatidylinositol phosphates (PIPs)(13, 17–19) in their conserved ligand binding 
domain (LBD). There are no protein crystal structures of mammalian OSBP/ORPs, but based on 
the protein crystal structures of the yeast OSBP/ORP homologs, the conserved LBD is a beta barrel 
comprised of 19 anti-parallel beta sheets(20). The OSBP/ORP homolog with the most extensive 
protein structure is the yeast protein Osh4, which has been co-crystallized with various sterols and 
oxysterols bound(20). The ligand binding pocket contains a hydrophobic tunnel and a flexible lid 
capable of shielding the bound ligand sterol from the aqueous environment(20) (Figure 3B). After 
transport, the lid opens and has a flat surface allowing for contact with the cell membrane and 
possible sterol targeting to the membrane(20). In addition to sterols and oxysterols being ligands 
for OSBP/ORPs, crystal structures of Osh4 have also been generated with PI4P bound in the 
LBD(21). The acyl chains of PI4P are stuck down in to the hydrophobic tunnel while the polar 
head group makes specific contact with the entrance and lid region(21).  
In order to bind both sterols and PI4P, OSBP/ORPs have various targeting domains besides 
their conserved LBD. OSBP/ORPs have an endoplasmic reticulum (ER) targeting domain (FFAT) 
that interacts with vesicle-associated membrane protein-associated proteins (VAPs)(22) and/or a 
pleckstrin homology (PH) domain that may interact with PIPs on various membranes(16, 23–26) 
(Figure 3A). ORPs can associate with two membranes through the binding of PIPs where the ORP 
will bind a ligand sterol, go through a conformational change, and deliver the sterol to the opposite 
membrane (Figure 4A). ORPs can also bind both PIPs and sterols in the same binding pocket, 
5 
creating an exchange of the two in opposite directions to modulate lipid compositions (Figure 4B). 
Endocytosis is controlled by ORPs through binding PIP, blocking transport factors and sending 
signals for metabolic regulation, and binding of sterols releases the ORPs and decreases the activity 
(Figure 4D). Longer ORPs associate with the ER through peptide motifs where oxysterol binding 
activates a PH domain to bind PIPs on a non-ER membrane contact site and recruit effector 




Figure 3: Homology and Basic Structure of Human ORPs. A) Protein domain homology graph 
showing the different OSBP/ORP families B) Structure model showing the beta-barrel of the ORP 
domain with the N-terminus lid interaction with 25-hydroxycholesterol shown. Figures A was 
created by Juan Nuñez & B is a screen shot from the yeast oxysterol binding protein Osh4 in 




Figure 4: Schematics of ORP/OSBP cellular pathway interactions. (A) Sterol transport 
between membranes using PIP’s as a docking site. (B) Binding sterols and PIPs in the same pocket 
in an exchange-like fashion. (C) Disassembly of ER complex with sterol binding. (D) Modulating 
endocytosis by blocking transport factors. (E) Binding to ER to activate effector proteins for signal 
transduction with oxysterol binding. 
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1.3 OSBP/ORP biology 
1.3.1 OSBP 
Oxysterol-binding protein (OSBP) was first described by its ability to bind oxysterols in 
vitro(27–29). In the early 1990s, OSBP gene was cloned and the OSBP protein was determined to 
be an 809 amino acid (~89 kDa) protein(10, 30). In the early 2000s, OSBP was recognized as 
being a member of a conserved protein family present in all eukaryotic cells(31, 32). The OSBP-
related proteins (ORPs) were identified based on the shared presence of a C-terminus ligand 
binding domain (LBD)(31). In addition to the LBD, OSBP also contains a PH domain located near 
the N-terminus that interacts with PI4P and ARF1 for trans-Golgi localization and a FFAT domain 
that interacts with VAPA on the ER membrane(33, 34). It was shown that upon ligand binding, 
the mostly cytocyolic OSBP would shift localization to membrane contact sites (MCS) consistent 
with trans-Golgi and ER staining(11). 
Multiple in vitro assays have shown the ability of OSBP to tether between the ER and 
Golgi membranes to counter transport cholesterol and PI4P(35, 36) (Figure 5). Use of a high 
affinity ligand of OSBP, 25-hydroxycholsterol, has also been shown to stop the counter transport 
and lead to aggregation of OSBP tethered particles, further confirming the ability of OSBP to bind 
to MCSs(35). Through these in vitro assays it was suggested that OSBP uses PI4P as a fuel source 
due to SAC1 hydrolysis of PI4P on the ER membrane, keeping the concentration gradient 
intact(35). Further studies in cells suggest that the major role of OSBP in cells is to control 
cholesterol transport through interacting with the kinase PI4KIIIβ(36). This kinase, which is 
responsible for making PI4P, and thereby OSBP can consume large quantities of PI4P in order to 
transport cholesterol to regulate the lipid compositions of various cellular membranes(36). In 
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addition to its cholesterol transport ability, OSBP is also able to recruit CERT to the Golgi for 
ceramide transport and SM production(37). This recruitment of CERT is presumably through 
OSBP’s association with ARF1 that leads to PI4KIIIβ stimulation of PI4P production, allowing 
inactive CERT to localize to the Golgi(38). This adds another level of OSBP’s ability to control 
overall lipid composition of cell membranes. 
  
Figure 5: OSBP Counter-transport schematic. (A) OSBP binds to PI4P at the Golgi using its 
PH domain which is stabilized by ARF1 and interacts with the ER using its FFAT domain that 
binds VAP-A. The LBD domain of OSBP binds cholesterol at the ER and (B) transports it to the 
Golgi membrane. (C) OSBP releases cholesterol into the Golgi membrane and the LBD then binds 
PI4P. (D) OSBP counter-transports PI4P from the Golgi to the ER membrane where it is then 
hydrolyzed by the ER-resident SAC1. 
1.3.1.1 Cell Signaling Role 
As mentioned before, OSBP/ORPs can take place in various cell signaling pathways 
through the binding of sterols(3, 4, 6, 8, 9). OSBP can be regulated by a cellular kinase or act as a 
scaffold for either kinases or phosphatases(37, 39, 40). OSBP activity has also been shown to be 
regulated by phosphorylation at Ser242 by PKD. A phospo-metic version of OSBP was shown to 
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have impaired Golgi localization and induced Golgi fragmentation(37). This is consistent with the 
mechanism of action of brefeldin A, which inactivates ARF-1 and leads to Golgi 
fragmentation(41). This phosphorylation leads to the masking of the PH domain and possibly the 
interaction with ARF1, which is essential for Golgi localization(37). This leads to an inactivated 
form of OSBP and disassociation from the MCS. PKD’s substrates also include PI4KIIIβ and 
CERT, leading to activation of the former and deactivation of the later(42, 43). These results 
support an OSBP mechanism of action in which PKD first phosphorylates PI4KIIIβ, leading to 
activation and production of PI4P. This production of PI4P then leads to recruitment of OSBP 
through its PH domain, which interacts with ARF1 in its active form. This in turn leads to more 
production of PI4P, allowing for the recruitment of CERT to the MCS. OSBP transports 
cholesterol for PI4P while CERT shuttles ceramide to make SM, and this activity is then controlled 
by PKD phosphorylation to preserve lipid raft formation and lipid homeostasis(37). 
One study found that OSBP is also involved in regulating the activity of the ERK1/2 
signaling pathway(39). This study suggested that cytosolic OSBP acts as a sterol sensor that under 
normal conditions when cholesterol is bound, the PH domain is masked and the conformation of 
the protein changes to associate with HePTP and PP2A, which are tyrosine and serine/threonine 
phosphatases(39). This complex is then able to deactivate ERK1/2 and will only dissociate when 
cholesterol levels are low or oxysterols bind to OSBP. Under these conditions the conformation 
10 
changes, opening the PH domain and the phosphatases are removed, allowing for localization to 
the Golgi where cholesterol can be replenished (Figure 6). 
OSBP also has interactions with the JAK2/STAT3 pathway to lead to gene expression of 
profilin-1. 7-ketocholesterol levels were shown to lead to an up-regulation of profilin-1 
transcription due to increased STAT3 activation, through JAK2 and OSBP(40). When the 
oxysterol binds, OSBP interacts with JAK2 and is phosphorylated at position 394, which leads to 
a conformational change that allows for STAT3 to interact with the OSBP/JAK2 complex and also 
becomes activated by JAK2 phosphorylation(40). Once activated, STAT3 can translocate to the 
nucleus and induce transcription of profilin-1 by binding to the gene promoter. This provides more 
evidence that OSBP maintains lipid homeostasis by acting as a sterol/lipid sensor, and through this 
sensing can modulate cell signaling in response to various ligand levels (Figure 7) 
Figure 6: OSBP in ERK signaling. When cholesterol is bound to OSBP it allows for the 
phosphatases PP2A and HePTP to complex with OSBP and dephosphorylate ERK. When 
cholesterol levels are low and oxysterol levels rise, oxysterol binding to OSBP allows for 
the complex to dissociate and OSBP then localizes between the ER and Golgi, allowing 






1.3.2.1 Variants and Tissue Specificity 
ORP4 is a protein of 916 amino acids that consists of an N-terminus PH and FFAT domain 
with a C-terminus ligand binding domain. OSBP shares the closest sequence similarity to ORP4 
than any other human ORP with 58% sequence identity on the DNA level and 64% on the protein 
level(44). Despite this high similarity in sequence, the two proteins are different in biological 
function. Unlike OSBP, ORP4 has three difference splice variants named: ORP4L, ORP4M, and 
ORP4S(12, 17). ORP4L is the longest splice variant with all 916 amino acids and targeting 
domains(12, 17, 44). ORP4M has a truncated PH domain that is predicted to be nonfunctional in 
binding PI4P(17). ORP4S is lacking the N-terminus PH domain altogether and a portion of the 
Figure 7: OSBP in JAK/STAT signaling. (A) OSBP binds an oxysterol which allows 
for JAK2 interactions leading to (B) OSBP phosphorylation and conformational change. 
(C) The new OSBP conformation allows for STAT3 to interact with the OSBP/JAK2 
complex leading to STAT3 phosphorylation. (D) Activated STAT3 is then able to 
translocate into the nucleus and increase the transcription of profilin-1.  
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ligand binding domain(12, 17). Whereas OSBP is ubiquitously expressed, ORP4 seems to be tissue 
specific with the highest levels being in brain, retina, heart, and kidney tissues(12, 44). ORP4 was 
also shown to be overexpressed in patients with chronic leukemia as well as various cancer cell 
lines(17, 45, 46). Like OSBP, ORP4L was shown to have high affinity for cholesterol and 25-
OHC, as well as bind PI4P and VAPA(12, 47). 
1.3.2.2 Ligand Binding and Cellular Localization 
Unlike OSBP, which is mainly cytosolic unless ligand bound(11), immunostaining has 
shown that ORP4L is loosely associated with vimentin intermediate filaments while ORP4S causes 
aggregation of the vimentin network(12). 
ORP4S induced aggregation is due to the loss of leucine repeats near the N-terminus of the protein 
based on mutational experiments with ORP4L and OSBP(47). Mutated OSBP proteins revealed 
that loss of the leucine repeats caused vimentin collapses like ORP4L, but the localization of OSBP 
was mostly cytosolic(47). Due to this cytosolic staining of OSBP, it was thought that OSBP does 
not directly interact with the vimentin network, but with ORP4L through its similar dimerization 
domain. Yeast-two hybrid analysis revealed that mutations in the dimerization domain of OSBP 
lead to loss of interaction with ORP4L while mutations in the leucine repeat region did not have a 
loss of interaction while mutating both regions on OSBP lead to rescuing of the vimentin 
network(47). These results suggest that ORP4L can interact with OSBP in a regulatory fashion. 
Despite the ability to bind cholesterol, oxysterols, and PI4P, ORP4L was not originally 
thought to localize to the Golgi or change localization at all upon treatment with these 
compounds(12, 17, 48). A recent study has shown that using a C-terminal tagged protein, that 
ORP4L does in fact translocate to the Golgi upon 25-OHC treatment or cholesterol depletion(49). 
ORP4L was shown to have perinuclear structures after 25-OHC treatment or cholesterol depletion 
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that were ligand independent as tested through mutations of ORP4L(49). This localization of 
ORP4L to the Golgi was OSBP and Golgi localized PI4P dependent and loss of ORP4L lead to 
loss of Golgi structure (49). These results suggest that OSBP localization to the MCS, which leads 
to increased PI4P production could lead to the recruitment of ORP4L either through direct 
interactions through the dimerization domain or through ORP4L’s PH domain targeting the 
increased PI4P pool. 
1.3.2.3 Vimentin Binding 
Vimentin has been shown to be involved with the recycling of LDL-derived cholesterol 
and recycling of glycosphingolipids from endosomes to the Golgi(50–52). Studies have shown 
that cells lacking vimentin have increased cholesterol synthesis and decreased cholesterol 
esterification, suggesting that vimentin plays a role in the transport of LDL-derived cholesterol 
from the endosomes(50). One of the ways that this might occur is through ORP4 binding to the 
vimentin network. Studies have shown that overexpression of ORP4S causes an aggregation of 
this network and results in a 40% reduction of LDL-derived cholesterol esterification(12). ORP4M 
was also shown to cause vimentin aggregation due to the non-functional PH domain, implying that 
the PH domain of ORP4L plays a role in preventing vimentin collapse(17). 
The sterol binding domain of ORP4L was shown to be capable of binding vimentin 
regardless of cholesterol or 25-OHC being bound to the protein. Cholesterol and 25-OHC binding 
was lost with the deletion of the α-helical lid and the first β-strand in the sterol binding region 
(residues 501-505), but vimentin binding was still retained(47). This suggests that ORP4L can 
interact with vimentin in either a ligand bound or free state. This provides evidence that ORP4 
interaction can regulate the transport of LDL-derived cholesterol from the endosomal 
compartments to the ER via the vimentin network. Consistent with the idea that ORP4 interacts 
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with vimentin to modulate cholesterol localization is that ORP4 knockdown in mice leads to male 
sterility(53). Knockout of ORP4 causes a condition known as oligo-astheno-teratozoospermia, 
which leads to low sperm count, low motility and abnormal morphology(53). Loss of ORP4 leads 
to mislocalization of the oocyte activation factor MN13, which needs to translocate from the sterol 
rich region of the sperm head to an almost sterol free location(53). The formation of the sperm 
head under normal ORP4 conditions shows significant ORP4 localization in the equatorial region, 
which also contains rich vimentin intermediate filaments and is a sterol rich region(53). These 
results suggest that functional ORP4 needs to interact with vimentin within the regions of the 
sperm head in order to translocate MN13 for efficient spermatogenesis.   
1.3.2.4 Role in Cellular Proliferation 
ORP4 has also been shown to be linked to cell survival and proliferation(17). Knockdown 
of all ORP4 variants, but not OSBP, was shown to cause growth arrest in HEK293 and HeLa cells, 
while overexpression of any one of the knockdown resistant variants partially prevented this 
arrest(17). Silencing ORP4L and not the ORP4M and  ORP4S variants, also caused a partial 
growth arrest in HeLa cells(17). These results suggest that ORP4 is required for cell line viability 
and proliferation. Knocking down of ORP4 in non-malignant IEC-18 cell lines lead to apoptosis 
through conventional pathways, and RAS transformations of IEC-18 cells had more total ORP4 
and did not go through cell death(17). This suggests that ORP4 may be overexpressed during the 
transformation of cells in order to make them immortalized. 
Another line of evidence that ORP4 is used for proliferation is its ability to promote 
oxidative phosphorylation in the mitochondria, driving cellular metabolism(48, 54). A recent study 
in T-ALL has shown that ORP4L acts as a scaffold/adaptor allowing for the assembly of CD3β, 
Gαq/11, and PLCβ3(54). This ORP4L-mediated complex activates PLCβ3 to process IP3 into 
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signaling molecules to induce the Ca2+ release from the ER used in oxidative phosphorylation(54) 
(Figure 8). This complex was also found to be active in macrophages, and in macrophages, the 
complex sustains cell viability through the ER Ca2+ release leading to c-AMP responsive element 
binding protein activation and upregulation of transcription of the anti-apoptotic factor Bcl-
XL(48). Disruption of this complex through ORP4L binding to 25-OHC leads to increased 
apoptosis due to the decrease in Bcl-XL transcription(48). 
 
Figure 8: Schematic of ORP4’s role in oxidative phosphorylation. ORP4 complexed with 
CD3β, Gαq/11, and PLCβ3. This complex leads to the activation of PLCβ3, which cleaves IP3 
into signaling molecules. These signaling molecules are then able to release Ca2+ from the ER into 
the mitochondria allowing for increased oxidative phosphorylation. 
 
1.3.3 Subfamily II: ORP1 and ORP2 
Unlike OSBP and ORP4, the subfamily II member ORP1 has two variants (ORP1L & 
ORP1S) which have very different expression patterns. The long form variant has been shown to 
found in brain, lung, and macrophages while the short form has highest expression in skeletal 
muscles and the heart(55). Similar to OSBP/ORP4, ORP1L has an FFAT domain that is able to 
bind to VAP proteins on the ER(13). ORP1L also has a PH domain that can bind PI4P(13). These 
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targeting domains allow it to carry out its function of removing cholesterol from late endosomes 
with the aid of Niemann-Pick C1 protein and PI4P and placing it into the ER membrane(13). In 
contrast, ORP1S has the ability to translocate into the nucleus upon ligand stimulation and bind to 
LXR, which promotes binding to LXR-responsive elements and leads to production of LXR-
dependent gene transcription, specifically the apoE gene(56). 
Like OSBP, ORP2 is ubiquitously expressed in all cell typess(57), but ORP2 is unique in 
the OSBP/ORP family in that only a short version of the protein is encoded(3). ORP2 binds neutral 
lipid membranes and has a possible cholesterol-mediated role in triglyceride metabolism(58). 
ORP2 has a FFAT domain that allows it to target the ER and was shown to be localized at lipid 
droplets (LD), suggesting it has a potential mediation effect in ER-LD association that allows for 
coordination of neutral lipid metabolism(59). ORP2 shares sequence similarity to ORP1S, and 
like-wise also binds LXR and promotes transcription of LXR target genes(60). 
1.3.4 Subfamily III: ORP3, ORP6, and ORP7 
ORP3, ORP6, andORP7 comprise subfamily III of the OSBP/ORPs. Similar to OSBP and 
ORP4, all of subfamily III have PH and FFAT domains(61). All of subfamily III have detectable 
expression in all cell types but ORP3 is highly expressed in kidneys, lymph nodes, and thymus(61). 
ORP3 interacts with R-Ras proteins to control cell adhesion and becomes phosphorylated when 
cells become un-adhered suggesting an outside-in feedback signals(62, 63). Hyper-
phosphorylation of ORP3 leads to multiple VAPA interactions at the ER and it is then able to 
contact the plasma membrane (PM) through its PH domain(63). This allows ORP3 to activate R-
Ras proteins giving rise to the idea that ORP3 plays a role in ER-PM communication(3, 63). 
ORP6 shows high expression in the brain and skeletal muscle tissue(61) and has been 
shown to be involved with regulation of cholesterol efflux and trafficking by affecting the early 
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lysosomal network(64). Similar to ORP3, ORP6 was shown to localize to the ER and ER-PM 
contact sites in cerebellar granule neurons(65). ORP6 is transcriptionally regulated by LXR in 
order to respond to intracellular cholesterol and is tightly controlled by cellular sterol levels(64). 
ORP7 expression is abundant in the gastrointestinal tract and has also been shown to 
localize to ER/PM(61) to interact with R-Ras proteins(3). ORP7 is involved in autophagy through 
sterol-ligand induced interactions with GATE-16, which induces degradation of the Golgi SNARE 
protein GS28 and subsequent addition of ORP7/GATE-16 complexes to autophagosomes(66). 
ORP7 was also identified as the only OSBP/ORP family protein that could associate with serum 
lipids and therefore ORP7 could have a role in gastrointestinal lipid absorption(67). 
1.3.5 Subfamily IV: ORP5 and ORP8 
Subfamily IV, consisting of ORP5 and ORP8, is unique to the rest of the OSBP/ORP family 
due to the presence of transmembrane domains. The transmembrane domains anchor the proteins 
directly to the ER without the need of the FFAT domains interacting with VAPA(15, 22). ORP5 
and ORP8 possess a PH domain and were shown to bridge the ER and PM by binding PI4P with 
their PH domain(68). This allows for the transport of phosphatidylserine (PS) from the ER to the 
PM with PI4P being counter-transported and hydrolyzed by SAC1 at the ER(68). This lipid 
shuttling system is similar to the OSBP counter-transport of cholesterol and PI4P(68). ORP5 and 
ORP8 are also able to utilize phosphatidylinositol-4, 5-biphosphate (PI(4,5)P2) for counter-
transport of PS at ER/PM(18). ORP5 and ORP8 have the ability to deliver PS from the ER to the 
mitochondria, which appears to be crucial to mitochondria function(69). ORP5 and ORP8 RNAi 
silencing leads to mitochondria dysfunction(69). 
Besides the overlapping functions exhibited by both proteins, ORP5 can extract cholesterol 
from LE(15) and also localize mTOR to lysosomes which is associated with cell proliferation and 
18 
migration(70). ORP8 on the other hand has implications in controlling lipid homeostasis and 
SREBP activity(71). ORP8 was shown to interact and localize with the nuclear membrane by 
binding with nuclear pore protein Nup62 and is thought to possibly dismantle the pore preventing 
SREBP entry into the nucleus(71). 
1.3.6 Subfamily V: ORP9 
ORP9 is expressed as both a long form (ORP9L) and short (ORP9S) form(72). Both 
ORP9L and ORP9S contain the FFAT domains that bind VAP proteins at the ER, but only the 
ORP9L possess the PH domain(72). ORP9L, like OSBP, has the ability to connect the Golgi and 
ER at the MCS using PI4P, and ORP9L can counter-transport cholesterol in a PI4P dependent 
manner(16). Silencing of ORP9L or overexpression of ORP9S leads to Golgi fragmentation, which 
parallels the destructive effect of expression of the phosphorylated-mimetic version of OSBP(73, 
74). Similar to OSBP, ORP9 is also a substrate for PKD phosphorylation and regulates activation 
of AKT, and through AKT, mTOR activation(75). Further support for the fact that ORP9 plays a 
role in the Golgi secretory pathway is the ability of ORP9S to phenocopy the OSBP yeast homolog 
Osh4P and mediate Golgi-derived vesicular trafficking(76). 
1.3.7 Subfamily VI: ORP10 and ORP11 
Subfamily VI is unique among the family in the fact that they do not contain an ER 
targeting FFAT sequence but do contain PH domains(3). ORP10 has a PH domain that interacts 
with PI4P and a LBD domain that binds cholesterol and several acidic phospholipids(23). ORP10 
is implicated in having a role in lipid metabolism(23). ORP10 localizes to microtubules 
presumably through its interaction with microtubule effector protein DIAPH1(23, 77). The PH 
domain of ORP10 has the ability to localize to the Golgi due to PI4P binding, and the protein plays 
a role in the secretion of apolipoproteinB-100(23). 
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ORP11 has been shown to reside at the Golgi complex and LE, which is presumably due 
to its ability to dimerize with ORP9(78). Along with ORP11, ORP10 can also dimerize with ORP9, 
which with its FFAT domain, might compensate for the lack of an ER targeting domain in 
subfamily VI(23). This information suggests that there is a possible crosstalk between two or more 
ORPs that allows for communication between the ER, Golgi, LE, and microtubules(23, 76, 78). 
1.4 OSBP/ORP Disease Relevance 
1.4.1 OSBP Function in Virus Replication 
OSBP has been implicated as an essential host protein in a wide variety of viral 
infections(79–84). The cholesterol shuttling ability of OSBP is hijacked by these viruses in order 
to carry out efficient replication within the host cell(79–84). To date OSBP function has been 
shown to be important in the replication of Hepatitis C, Enterovirus genus, 
Encephalomyocarditis, and Dengue viruses(79–84).      
1.4.1.1 Hepatitis C Virus 
Hepatitis C (HCV) virus is a member of the Flaviviridae family that has no preventable 
treatment other than host behavior changes. HCV currently infects about 3% of the world 
population(85). HCV was one of the first viruses that was linked to OSBP’s ability to shuttle 
cholesterol(79). HCV is a positive-sense strand RNA virus that forms a protrusion replication 
organelle (RO), where the donor membrane is bent into the cytoplasm(86). These ROs can be 
single or double membraned structures that are dynamic and form membranous webs with their 
integrity based on cholesterol and PI4P(87, 88). Viral protein NS5A recruits and activates 
PI4KIIIα at the RO membrane, which leads to the upregulation of PI4P production(89, 90). This 
increase in PI4P then leads to recruitment of OSBP and CERT to the membrane for cholesterol 
and sphingomyelin efflux to the RO membrane(79, 91, 92). Disruption of the PI4K/PI4P/OSBP 
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pathway through means of chemical or translational inhibition leads to reduction of viral 
replication. 
PI4KIIIβ has also been shown to be involved with OSBP recruitment to ROs in other 
variants of HCV, but it is suggested that its role is more essential for secretion of viral partials(93). 
Inhibition of PI4KIIIβ has been shown to inhibit egress of virion particles without affecting virion 
replication(94). Depletion of cholesterol or sphingomyelin from HCV virions has been shown to 
decrease infectivity of the viral particles, suggesting these two molecules may play a role in 
efficient entry of the virus into cells(95). OSBP’s ability to interact with PI4KIIIβ and stimulate 
sphingomyelin synthesis via CERT, provides evidence of OSBP having multiple roles in virus life 
cycle. 
HCV egress from the cell has been linked to the host secretory pathway, specifically the 
utilization of very low density lipoprotein (VLDL) to form lipoviroparticles (LVPs)(96). The LVPs 
have been shown to bind to low density lipoprotein receptors (LDLRs) on the cell surface, 
facilitating viral entry into the host(97). HCV’s usage of the LDLRs provides not only efficient 
entry, but also sustained viral replication(98). HCV increases LDLR expression through 
stimulation of sterol-regulatory binding proteins (SREBPs), which results in increased LDL 
particle uptake from the bloodstream(98). Overexpression of OSBP in hepatocytes has been shown 
to increase SREBP-1c expression, which in turn increased VLDL production(99). This information 
provides further evidence that OSBP may have a broader effect in the HCV life cycle beyond just 
viral replication. 
1.4.1.2 Enteroviruses 
The genus Enterovirus are positive-sense strand RNA viruses in the family Picornaviridae 
and encompasses a variety of important human pathogens. The most famous member of the genus 
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is poliovirus (PV) due to its historical notoriety as the causative agent of poliomyelitis. In 1988 
the World Health Organization (WHO) started the Global Polio Eradication Initiative and in 2017 
there were only 22 cases reported worldwide compared to ~350,000 cases when the initiative 
started(100). The eradication of polio is due to the development of an oral PV vaccine (OPV) that 
is feasible to administer but has drawbacks due to the ability of the OPV to revert back to vaccine 
derived PV (VDPV)(101). In areas where the community is under vaccinated, this VDPV can 
spread from person to person and is then considered chronic VDVP (cVDVP) and is as severe as 
wild PV(101). While there were only 22 cases of wild PV reported in 2017, there were 96 cases 
of cVDPV(100). This suggests the need for antiviral therapies to help control cVDPV to help in 
the eradication of PV. Recently, OSBP was shown to have a role in the replication cycle of PV 
and disruption of OSBP function through protein knockdown or small molecule inhibitors lead to 
a decrease in PV replication(80). Targeting OSBP could be a potential strategy to control cVDPV.  
Other Enterovirus species include Human Rhino Virus (HRV), numbered enteroviruses 
(eg. EV71, EV68), Coxsackievirus (CV), and Echovirus. These viruses affect millions of 
individuals each year and include illnesses that range in severity such as the common cold and 
viral conjunctivitis to more serious diseases such as viral meningitis/encephalitis and acute flaccid 
paralysis(102). HRV infections cause over 50% of cold-like and flu-like illnesses, and are an 
enormous economic burden, costing billions of dollars annually(103, 104). Infections can be linked 
to asthma in children and is a significant cause of acute respiratory illness in immune compromised 
patients(103, 104). Within the past two decades, outbreaks of EV71 and EV68 have become public 
health concerns, especially for infants and young children(105–107). Both serotypes of the virus 
have been shown to cause acute flaccid myelitis and other severe neurological conditions(105–
107). EV71 and CV are some of the most causative agents of hand, foot, and mouth disease and a 
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recent outbreak in China between 2008-2012 resulted in over 7 million cases with over 2500 
deaths(105, 106). Echoviruses are among the most common cause of meningitis and can also cause 
myocarditis and development of type 1 diabetes(108). Unlike PV, due to the large number of 
serotypes, the non-polio enteroviruses do not have a vaccine and there currently are no approved 
antiviral treatments. 
Enterovirus species encode a single protein of about 250kDa that is processed by viral 
proteases to make structural and non-structural proteins. Like HCV, these viruses also induce a 
protrusion-type RO which are thought to shield the RNA in the cytoplasm from host defenses and 
support replication(109). The virus needs to modulate the lipid composition of the membrane to 
retain integrity of the membrane to sustain efficient replication, and to do this it hijacks host 
proteins involved in lipid metabolism(110). Viral protein 3A has been shown to play a role in the 
RO formation by recruiting host factors ARF1 and GFB1 to the membrane, which in turn recruits 
PI4KIIIβ to increase PI4P production at the RO(111–113). OSBP can localize to these ROs 
through its normal interactions with ARF1 and PI4P targeting and disruption of OSBP function 
leads to broad enteroviral inhibition due to OSBP’s role in cholesterol shuttling in response to 
PI4KIIIβ derived PI4P accumulation at ROs(81, 114). The viral RNA-dependent RNA-
polymerase, 3Dpol, was shown to have specificity in binding PI4P in vitro which suggests that PI4P 
may act as a scaffold at ROs for viral protein localization for assembly of genome replication 
machinery(112). Another component of RO generation is the accumulation of cholesterol from 
various host membranes(114). Enteroviruses have been shown to extract cholesterol from the ER, 
lipid droplets, and recycling endosomes from increased endocytosis, and disruption of cholesterol 
homeostasis leads to decreased viral replication(114–116). The dependence of these viruses on 
cholesterol suggests that OSBP would be a favorable host target for antiviral therapies. 
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1.4.1.3 Role of OSBP in the Replication of Other Viruses 
Encephalomyocarditis virus (EMCV) is a positive-sense strand RNA virus belonging to 
the genus Cardiovirus that is responsible for fatal myocarditis and encephalitis in various animals 
with no current treatment. The main reservoir for EMCV is thought to be rodents, and although 
EMCV infects a variety of animals, pigs seem to be the most susceptible(117). EMCV infection is 
thought to be fairly common in humans with up to 17% of various town populations being 
seropositive to EMCV, but despite the common exposure there are rarely any symptoms 
reported(117). One potential human health issue that could arise is the use of pig heart tissue for 
xenografts in humans. The common occurrence of the virus and its specificity for pig heart tissue 
could destroy the xenograft tissue quickly leading to patient complications.  
Recent studies have shown that EMCV utilizes the same pathway as HCV for viral 
replication(83). EMCV hijacks PI4KIIIα, which associates with viral protein 3A at the RO to 
recruit OSBP. OSBP is recruited to counter transport PI4P for cholesterol at the RO(114). 
Disruption of the function of either OSBP or PI4KIIIα prevent viral replication(114). Interestingly, 
single point mutations in 3A that lead to resistance to PI4KIIIα small molecule inhibitors did not 
confer resistance to OSBP inhibitors(118). This suggests an uncoupled function of PI4KIIIα and 
OSBP in the virus replication(118).  
Dengue virus (DV) is a positive-sense strand RNA virus in the Flaviviridae family that is 
transferred by an arthropod vector to humans. DV causes dengue hemorrhagic fever and dengue 
shock syndrome(119). DV has four closely related serotypes and infection with one serotype can 
make reinfection with a different serotype more dangerous(120, 121). More than two fifths of the 
world’s population is at risk for possible dengue infection and the development of a vaccine to 
cover all the serotypes is a slow process with many challenges(119). Unlike the other viruses 
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mentioned earlier, DV makes an invagination RO into the ER which is PI4KIII independent(122). 
Despite the lack of PI4KIII dependency, inhibition of cholesterol biosynthesis or cholesterol 
depletion was shown to be antiviral towards DV(123). A recent study has shown that OSBP is 
involved in DV replication. Knockdown of OSBP and use of OSBP inhibitors was shown to inhibit 
DV replication and cause a redistribution of cellular cholesterol(84). This new study solidifies the 
role that OSBP plays in a broad spectrum of viral infections and signifies the potential therapy 
OSBP targeting could provide. 
1.4.2 Cancer Cell Survival and Proliferation 
ORP4 and OSBP were originally identified as the target of various natural product 
compounds that showed anti-cancer activity in various cultured human cancer cell lines(46). This 
study showed that overexpression of either protein resulted in an increased resistance to the 
compounds and that loss of OSBP resulted in increased sensitivity of the compounds(46). ORP4 
was originally identified as a potential molecular marker for solid state tumors due to its mRNA 
overexpression in patient blood and tissue samples of lung and breast cancer(124). In a subsequent 
study ORP4 was shown to be overexpressed in chronic myeloid leukemia from patient samples as 
well as several cultured cell lines derived from various forms of leukemia(45). Knockdown of 
ORP4 resulted in cellular growth arrest in cancerous and immortalized cultured cell lines and 
apoptosis of non-transformed cells(17). Consistent with the finding that ORP4 is utilized in the 
oncogenesis/transformation of cells was the finding that ORP4 mRNA expression was increased 
when the human papilloma virus proteins E6 and E7, which can immortalize cell lines in vitro, 
were transfected into cells(124). A recent study has shown that ORP4L is expressed in T-cell acute 
lymphoblastic leukemia (T-ALL) but not normal T-cells(54). ORP4L in the T-ALL cancer cell 
was linked with an increase in oxidative phosphorylation through calcium signaling(54). ORP4’s 
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link with various forms of cancer and cell survival provide an attractive target for anti-cancer 
strategies due to its limited tissue expression as previously mentioned. 
1.5 ORPphillins and OSBP/ORP4 
A variety of small molecule inhibitors of OSBP and ORP4, termed ORPphillins, have been 
identified through the screening of these compounds as anti-cancer and antiviral agents(46, 80, 81, 
125). These compounds range from steroidal based natural products to synthetic triazoles(46, 80, 
81, 125). Despite the diversity of structures, most of the compounds exhibit the ability to inhibit 
OSBP function in vitro, but many of the cellular effects on OSBP and ORP4 remain unknown for 
these compounds(46, 80, 81, 125).        
1.5.1 OSW-1 
The natural product OSW-1 (Figure 9), (3β,16β)-3,17-Dihydroxy-22-oxocholest-5-en-16-
yl-2-O-acetyl-3-O-[2-O-(4-methoxybenzoyl)-β-D-xylopyranosyl]-α-L-arabinopyranoside, was 
originally extracted from bulbs of Ornithogalum saundersiae, a Star-of-Bethlehem plant found in 
South Africa, in 1992 and was shown to have considerable activity against cyclic AMP 
phosphodiesterase(126). It was later shown that OSW-1 had significant anti-proliferative effects 
against various tumor derived cell lines and had a mean IC50 of 0.78 nM in the National Cancer 
Institute 60-cell in vitro screen (NCI60)(127). The target of OSW-1 was identified to be OSBP 
and ORP4(46). OSW-1 was shown to cause proteasome dependent degradation of OSBP in a time 
dependent manner(128). OSW-1 has been shown to cause disruption of intracellular calcium 
leading to mitochondria membrane disruption and calcium dependent apoptosis(129). Further 
research has also shown that OSW-1 causes a disruption of cellular calcium homeostasis which 
affected the mitochondria and the survival factor GRP78 which lead to apoptosis in leukemia 
cells(130). This mechanism of action coupled with the idea that increased ORP4L is tied to 
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oxidative phosphorylation through intracellular calcium signaling in T-ALL cells(54) suggests that 
ORP4 is the anticancer target of OSW-1. 
OSW-1 has been shown to have antiviral activity(81, 82). OSW-1 was first shown to have 
antiviral activity against HCV due to the disruption of OSBP function and the resulting loss of 
cholesterol to ROs(92). It has also been shown to be a broad spectrum antiviral against 
Enteroviruses through the disruption of OSBP shuttling cholesterol to ROs which affected genome 
replication of the viruses(81, 82). OSW-1 treatment was also recently shown to reduce DV 
replication presumably through the disruption of cellular cholesterol homeostasis due to impaired 
OSBP function(84). These findings suggest that OSBP is the antiviral target of OSW-1, while the 
anti-cancer target is ORP4. 
 
Figure 9: Structure of OSW-1 
 
1.5.2 Schweinfurthins 
Schweinfurthins (A-C) were originally isolated from Macaranga schweinfurthii, a 
flowering tree in the spurge family found in Cameroon, in 1998 and A (Figure 10) and B were 
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shown to have cytotoxic activity with a mean NCI60 IC50 value of 360 nM and 810 nM 
respectively(131). Further isolations from M. schweinfurthii revealed Schweinfurthin (D, I, and J) 
while isolations from two other species in the Macaranga genus yielded 11 other Schweinfurthins 
lettered to Q with Schweinfurthin F having the lowest mean NCI60 IC50 value of 130 nM(132–
134). Schweinfurthin A was shown to bind to OSBP in the low nanomolar range while ORP4 
binding was in the low micromolar range(46). Unlike OSW-1, Schweinfurthin A does not cause 
OSBP protein degradation(46). A recent study has shown that Schweinfurthin G (Figure 10) 
inhibits mTOR/AKT cancer cell proliferation through disruption of the trans-Golgi network 
(TGN)(135). Schweinfurthin G was shown to bind with OSBP and increase its affinity for PI4P, 
suggesting that the interaction might lead to sequestration of PI4P trafficking that leads to TGN 
disruption(135). Schweinfurthin A presents as an interesting candidate for an antiviral drug due its 
selectivity for OSBP over ORP4 but the limited availability due to supply issues presents an 
obstacle to overcome(136). 
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Figure 10: Structures of Schweinfurthins that bind OSBP. Schweinfurthin A (1) and G (2). 
1.5.3 Cephalostatin 1 and Ritterazine B 
Cephalostain 1 (Figure 11) was originally collected in extracts from the marine worm 
Cephalodiscus gilchristi off the coast of Southeast Africa in 1972 and was not fully characterized 
until 1987(137). Cephalostatin 1 has a mean NCI60 IC50 value of 2.2 nM(137, 138). Another 
marine extracted natural product with a structure related to cephalostatin 1 and possessing potent 
cytotoxicity is ritterazine B (Figure 11) (139). Ritterazine B was isolated from the tunicate 
Ritterella tokioka  collected off the coast of Japan in 1995(139). Ritterazine B has a mean NCI60 
IC50 value of 3.2 nM which is comparable to that of Cephalostatin 1(140). Both of these compounds 
were shown to bind OSBP with low nanomolar affinity(46). Cephalostatin 1 also has low 
nanomolar affinity for ORP4(46). Ritterazine B did not bind ORP4L as well as cephalostatin 1, 
but a inhibition binding value could not be determined due to lack of sufficient compound(46). 
Interestingly, cephalostatin 1 was also able to induce OSBP degradation upon treatment similar to 
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OSW-1(46). Neither of these compounds has been tested for antiviral activity and do not seem 
feasible to pursue due to their limited availability and time intensive synthesis(141). 
 
Figure 11: Structures of Cephalostatin 1 and Ritterazine B. 
 
1.5.4 Itraconazole 
Itraconazole (ITZ) (Figure 12) is a synthetic triazole created in 1983 by a division at 
Janssen Pharmaceutica in Belgium as a broad spectrum anti-fungal agent(142, 143). The anti-
fungal mechanism of action of ITZ is by inhibiting the cytochrome P450 34A enzyme responsible 
for synthesizing ergosterol, which is an essential fungal sterol (144). ITZ gained FDA approval for 
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anti-fungal use in 2001(145). ITZ has been identified as a hit in drug repurposing screens for anti-
cancer and antiviral compounds(146, 147). The anti-cancer activity of ITZ, which is separate from 
its anti-fungal activity, stems from its ability to inhibit both angiogenesis through the process of 
disruption of mTOR signaling and vascular endothelial growth factor receptor 2 trafficking, and 
also through effecting the hedgehog pathway signaling(148–150). ITZ’s ability to broadly inhibit 
virus replication is independent of its anti-fungal and anti-cancer activities, and it occurs through 
inhibiting OSBP and possibly ORP4(81). ITZ was shown to bind OSBP with a Kd of 430 nM(81). 
ITZ treatment of cells alters OSBP localization patterns, and like OSW-1, ITZ treatment of cells 
inhibits the cholesterol and PI4P counter transport that is necessary to fuel RO viral replication(81). 
Pursuing ITZ as an OSBP inhibitor seems feasible due to its established FDA approval, but the 
lack of specificity due to the multiplicity of targets and the extremely poor water solubility of the 
compound are potentially limiting(151). 
 
Figure 12: Structure of Itraconazole. 
1.5.5 Minor Enviroxime-like Compounds 
Enviroxime is a compound that inhibits positive-strand RNA viral synthesis by indirectly 
targeting viral proteins 3A and/or 3AB(152, 153). This interaction prevents the replication 
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complex from forming properly(152, 153). Mutations in the viral 3A and/or 3AB proteins leads to 
resistance to the compound(152, 153). Enviroxime-like compounds are compounds with anti-viral 
activity that are structurally-unrelated to enviroxime, but the same mutations that confer resistence 
to enviroxime also confer resistance to the enviroxime-like compounds(154). The enviroxime-like 
compounds can be further classified as major or minor compounds, with major compounds being 
PI4KIIIβ inhibitors and the minor compounds being non- PI4KIIIβ inhibitors(155). The minor 
enviroxime-like compound T-00127-HEV2 (Figure 13) (THEV2) was shown to have increased 
anti-poliovirus activity when OSBP was knocked down(155). Further, cellular treatment with 
THEV2 led to OSBP localization to the Golgi, similar to 25-OHC treatment, and a corresponding 
decrease of PI4P at the Golgi(155). Similarly, the minor compound TTP-8307 (Figure 13) (TTP) 
was also shown to exert its anti-viral activity through the targeting of OSBP(156). TTP was shown 
to inhibit the in vitro cholesterol transferring ability of OSBP and to cause localization of the 
protein to the Golgi similar to other known OSBP interacting compounds(156). Interestingly, 
overexpression of OSBP in infected cells did not lead to viral resistance to the TTP compound, 
suggesting this compound might also interact with other components in the viral replication 
pathway beyond OSBP(156). Further analysis of these THEV2 and TTP compounds biological 
activity is required to define their interaction with OSBP and evaluate their potential efficacy as 
antiviral lead compounds. 
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Figure 13: Structures of minor enviroxime-like compounds that target OSBP. 
 
1.6 Small Molecule Drug Targets 
There are currently over 2300 FDA approved small molecule drugs(157) for a variety of 
targets and diseases, which can be utilized as chemical probes to understand functions of proteins 
and various biological processes(158). The latter chapters of this dissertation explore the cellular 
effects of ORPphilin inhibition of OSBP. Small molecule inhibitors to key cellular pathways, such 
as the proteasome and autophagy, are utilized to determine the fate of OSBP inhibited by these 
ORPphillins. The cellular processes, and their small molecule inhibitors, that are explored in the 
subsequent chapters are briefly outlined in the following section.   
1.6.1 Proteasome Overview 
The proteasome is a large protein complex that is responsible for degradation of cellular 
proteins tagged by the ubiquitin post translational modification(159, 160). Addition of 
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polymerized ubiquitin on a protein serves as a degradation signal to target the protein to the 
proteasome(159, 160). Ubiquitination is performed by a network of proteins: E1, E2, and E3(159, 
160). E1 proteins are ubiquitin activators that obtain ubiquitin and transfer it to the E2 ubiquitin-
conjugating enzymes(159, 160). The E2 enzymes complex with the E3 ubiquitin-ligating enzymes 
and the protein substrate (159, 160). E3 proteins are substrate selective and there are more than 
500 different E3 proteins to accommodate the cellular protein substrates in need of 
polyubiquitination(161). Once polyubiquitination has occurred, the protein substrate is released 
and is then targeted to the proteasome complex. This complex consists of one or two 19S 
regulatory particles (RP) that serve to remove the ubiquitin tags and unfold the protein(161). The 
unfolded protein is fed into the 20S catalytic unit of the proteasome which degrades the protein 
into peptides of 3-15 amino acids, which are further degraded by oligopeptidases and/or amino-
carboxyl peptidases to generate amino acids(161). The proteasome complex degrades ~80% of 
intracellular proteins, and the proteasome plays a vital role in major cellular processes such as in 
the cell cycle, cellular stress response, protein quality control, immune system functions, and 
apoptosis(162–164). In recent years, proteasome inhibition has been shown to have anti-cancer 
activity(165) and be a potential anti-inflammatory therapy(166). Inhibition of the proteasome has 
also advance basic cell biology through knowledge gained about the cell cycle, transcriptional 
response, metabolic regulation,etc(167). 
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1.6.2 Proteasome Inhibitors 
Figure 14: Structures of Various Proteasome Inhibitors. 
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1.6.2.1 Peptide aldehydes: MG132 & ALLN 
Peptide aldehydes were the first class of proteasome inhibitors to be developed, and these 
compounds are widely used as research agents to inhibit the proteasome (168). In general, these 
inhibitors rapidly enter the cell, but have slow and reversible binding to the proteasome(169, 170). 
Peptide aldehydes are subject to rapid oxidation into inactive forms in the cells, and this means 
that proteasome inhibition can be rapidly reversed by removing the inhibitor from the cell media 
(169, 170). ALLN (Figure 14, [2]), was first described as an inhibitor of the calcium-dependent 
proteases known as calpains(171), but  ALLN was also shown to have proteasome inhibitor 
activity, albeit with ~25-fold less selectivity for the proteasome to the calpains(168, 172). In 
contrast, MG132 (Figure 14, [1]), is more potent and selective for the proteasome than ALLN(173, 
174). Ten-fold higher concentrations of MG132 are required to inhibit calpains than the 
proteasome(173, 174). Due its potency, commercial availability, and low cost, MG132 is a primary 
reagent used to study proteasomal involvement on cellular activity(168). 
1.6.2.2 Peptide boronates and epoxyketones: Bortezomib and Carfilzomib 
Unlike the peptide aldehydes, peptide boronates are more selective for the proteasome 
compared to other cellular proteases, take longer to dissociate from the proteasome, and are less 
prone to metabolic inactivation in cells(168). Bortezomib (Figure 14, [3]) was the first approved 
proteasome inhibitor for use as an anti-cancer treatment(175). Bortezomib binds reversibly to the 
proteasome but the drug-receptor complex remains stable for several hours(176, 177). 
Peptide epoxyketones are the most selective proteasome inhibitors due to their selective 
irreversible binding to only the proteasome(168, 177). The covalent modification of the 
proteasome requires the generation of new proteasome subunits in order to regain function(168, 
177). Carfilzomib (Figure 14, [4]), which has also been approved for anti-cancer treatment, is a 
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second generation proteasome inhibitor that is a modified version of an early naturally occurring 
epoxyketone that has been shown to bind irreversibly to only the proteasome and not target any 
other cellular proteases(177, 178). These more selective proteasome inhibitors are utilized to 
confirm the role of a suspected proteasome target identified by MG132. 
1.6.3 Proteasomal Degradation induced by compounds 
Bioactive small molecules can induce the proteasomal degradation of cellular proteins 
through both direct and indirect interactions(46, 130, 179–183). Small molecule binding to the 
Hsp90 family of chaperone proteins leads to degradation of various proteins due to their inability 
to fold properly, including signaling proteins (183). Small molecule binding of targets that induce 
proteasomal degradation of that specific target usually target enzymes or receptors. The FTY720 
small molecule compound both inhibits and induces the proteasomal degradation of sphingosine 
kinase 1 (SK1)(181, 182). Chimeric small molecules have been developed that are capable of 
inducing the proteasomal degradation of select targets(179, 184). These compounds interact with 
the protein target but also contain a structural domains capable of recruiting specific E3 ligases for 
polyubiquitination(179, 184). The natural product compound OSW-1 induces the proteasomal 
degradation of the OSBP protein(46). This is a unique instance of a small molecule inducing the 
proteasomal degradation of a non-enzymatic receptor through a direct interaction(46). 
1.6.4 Autophagy Overview 
Autophagy is a cellular mechanism that is designed for degradation and recycling of 
cellular components(185). Autophagy is a highly conserved process in eukaryotes which(185). 
There are three distinct types of autophagy but macroautophagy is the most well studied form due 
to its involvement with in nutrient regulation and cell survival(186). The basic progression of 
autophagy occurs through induction and the formation of a phagosome to engulf the cargo 
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designated for recycling(187). The process of phagosome formation goes through an elongation 
step to form an autophagosome before eventually fusing with the lysosome(187). 
Initiation of autophagy occurs when the kinase mTORC1 dissociates from the unc-51-like 
kinase 1 (ULK1) induction complex(188). Once dissociated, ULK1 becomes activated, 
translocating to autophagy initiation sites, and recruits the vacuolar protein sorting 34 (VPS34) 
complex consisting of Beclin-1, ATG14, and class III phosphatidylinositol 3-kinase(187). This 
new complex of ULK1 and recruits the ATG12-5-16 and ATG8-LC3 ubiquitin-like complexes to 
expand the phagophore until it fully matures(187). At this point, the autophagoasome closes and 
fuses with the lysosome(187). 
1.6.5 Autophagy Induces and Inhibitors 
Rapamycin (Figure 15) is an anti-fungal(189) and immunosuppressive(190) natural 
product compound originally from a soil sample bacterium in 1972(191). Identifying the cellular 
target of rapamycin lead to the discovery of the mammalian target of rapamycin (mTOR) 
proteins(191). mTOR forms two complexes in cells (TORC1 and TORC2)(191). As stated above, 
autophagy is induced when the mTORC1 complex dissociates from the initiation complex(191). 
Rapamycin is used to induce autophagy in cellular experiments(192, 193). In order to monitor the 
induction of autophagy and the autophagic flux triggered by rapamycin, the conversion of LC3-I 
to LC3-II and the subsequent degradation of LC3-II are cellular markers of autophagy(192, 194). 
In addition to LC3 monitoring, which is an indicator of early autophagy, the protein p62 is 
selectively degraded during autophagy, and p62 degradation is a marker of autophagic flux(192). 
Another common reagent used to measure autophagic flux is the inhibitor compound chloroquine 
(CQ) (Figure 15) (192). CQ blocks the fusion of the autophagasome with the lysosome and this 
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prevents the autophagocytic degradation of proteins, including the proteins used as markers of 
induction of autophagy (195). 
 
Figure 15: Structures of an Autophagy Induce and Inhibitor. 
1.6.6 Cycloheximide 
Cycloheximide (Figure 16) (CHX), originally isolated from bacteria, is an inhibitor of 
eukaryotic protein synthesis(196). CHX has blocks the elongation phase of translation by binding 
to the ribosome and inhibits the eEF2-mediated translocation step from the A to the P site(196, 
197). The exact mechanism of CHX translation inhibition is still unknown, but it is thought that 
CHX requires a deacylated tRNA bound to the E site of the ribosome in order to exert its 
effects(196, 198). Due to this ability to inhibit protein synthesis, CHX is used as a cellular reagent 
to determine the half-life of proteins in cells(199). 
39 
 



















Chapter 2: Persistent Reduction of Oxysterol-binding Protein Caused by 
Compound Treatment Induces Prophylactic Anti-Viral Activity 
The following chapter is partially taken from the publication in ACS Chemical Biology by the 
author of this dissertation: Persistent, Multi-Generational Reduction of Oxysterol-Binding Protein 
Caused by Compound Treatment Induces Prophylactic Anti-Viral Activity. This was a 
collaborative work that consists of the following authors: Brett L. Roberts, Zachary C. Severance, 
Ryan C. Bensen, Anh T. Le, Naga Rama Kothapalli, Juan I. Nuñez, Hongyan Ma, Si Wu, Shawna 
J. Standke, Zhibo Yang, William J. Reddig, Earl L. Blewett, Anthony W. G. Burgett.  
Mr. Zachary Severance conducted the experiments in Figure 17, Figure 18, Figure 19 and 
Figure 22 using the HEK293 and HeLa cell lines. 
Mr. Ryan Bensen conducted the experiments in Figure 17, Figure 18, Figure 22 and Figure 
23 using the HCT116 cell line. 
Ms. Hongyan Ma conducted the bottom up proteomic MS experiment in Figure 19 
Ms. Shawna Standke conducted the LCMS and SCMS experiments in Figure 23. 
Dr. Earl Blewett conducted the anti-viral experiments in Figure 24.  
2.1 Abstract 
Oyxsterol-binding protein (OSBP) is the founding member of a highly conserved protein 
family found among eukaryotes that transports cholesterol and lipids among cellular membranes 
to maintain lipid homeostasis. OSBP has been implicated as a necessary host factor for viral 
replication among a wide variety of viruses, especially enteroviruses. The natural product OSW-1 
has anti-viral properties due to its selective inhibition of OSBP function. We have discovered that 
short-non lethal doses of OSW-1 followed by removal of the compound can induce ~90% 
reduction of OSBP protein levels for multiple days in a variety of cell lines. We have termed these 
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experiments “washouts” and have shown that the persistent effect of the initial treatment is not due 
to residual compound lingering in the cells. The “washout effect” occurs in all cell lines tested, 
and can occur within as little as 45 minutes of exposure at near sub nanomolar doses. As expected, 
continual treatment of cells with OSW-1 leads to lowered viral titers of two clinically isolated 
enteroviruses. Surprisingly, washout treated cells showed anti-viral activity towards the viruses, 
despite the compound being removed from the cells 24 hours prior to infection. Our results show 
that OSW-1 could be a powerful new prophylactic anti-enteroviral by repressing the host protein, 
OSBP, for multiple days without noted toxicity.                
2.2 Introduction 
OSBP is a lipid transport protein that is able to bridge the ER and Golgi using its various 
targeting domains in order to exchange cholesterol for PI4P(35, 36) (see section 1.3.1 OSBP). The 
closest homolog of OSBP, ORP4, shares significant sequence similarity (Figure 34) but has select 
tissue expression and performs different biological functions(44, 54) (see section 1.3.2 ORP4). 
OSBP is known to be involved with various cellular signaling pathways(39, 40) (see section 
1.3.1.1 Cell Signaling Role) while ORP4 has roles in cellular proliferation(17) (see section 1.3.2.3 
Role in Cellular Proliferation). Despite the knowledge of OSBP/ORP4s role in specific cellular 
functions, close to nothing is known about their regulation within cells. 
The natural product OSW-1 is a selective inhibitor of both OSBP and ORP4, which can 
induce proteasomal dependent degradation of OSBP over time(46) (see section 1.5.1 OSW-1). 
The effect of OSW-1 on ORP4 is not known, but it can be speculated that ORP4 is also degraded 
in a similar manner due to OSBP and ORP4 having dimerization domains(12) (see section 1.3.2.2 
Ligand Binding and Cellular Localization). The mechanism of how OSW-1 induces the 
degradation of OSBP, and the duration of the degradation remains a mystery.    
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OSBP, and to a lesser extent ORP4, have been implicated as a necessary host protein 
required for viral replication(81) (see section 1.4.1 OSBP Function in Virus Replication). OSBP 
has been shown to be essential for Enterovirus replication, which are major public health 
menace(81, 82) (see section 1.4.1.2 Enteroviruses). OSW-1 has been confirmed as an anti-viral 
compounds through its inhibition of OSBP(82) (see section 1.5.1 OSW-1). This suggests that 
OSW-1 could be a potential therapeutic for Enterovirus species due to the degradation of a host 
protein that has been shown not to influence cell survival. 
Herein we describe the discovery that the treatment of mammalian cells with a single, non-
toxic dose of the OSW-1 compound induces a significant reduction of OSBP protein levels that 
lasts for several days after the brief exposure to the compound. The reduction of OSBP levels 
remains even after the intracellular soluble OSW-1 compound concentrations have dropped to 
undetectable levels, and these cells have undergone multiple rounds of cell division. Triggering 
the persistent reduction of OSBP levels with the OSW-1 compound reduces the replication of two 
Enterovirus pathogens 24 hours after the compound is removed from the cell media. The inhibition 
of viral replication by triggering the reduction of a required host protein through small molecule 
treatment could be a new modality of anti-viral prophylaxis and potential therapeutic development. 
2.3 Results 
2.3.1 Constant OSW-1 compound treatment leads to a differential time dependent reduction of 
OSBP and ORP4 protein levels. 
The OSW-1 compound binds to both OSBP and ORP4 with similar affinity(46). 
Additionally, OSW-1 compound treatment of cells is reported to cause a loss of OSBP in a time 
dependent manner(46), but effects of OSW-1 treatment on the pro-proliferation protein ORP4 are 
unknown. 1 nM OSW-1 compound treatment showed >90% reduction of OSBP levels after 24 
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hours while also showing an average of ~50% reduction of ORP4 levels during the same time 
frame (Figure 17A). This result, as far as we are aware, is not only the first instance where cellular 
levels of ORP4 protein have been analyzed after treatment with OSW-1 compound, but also the 
first to show ORP4 is lost in a similar manner as OSBP. Although novel, this event is not surprising 
since prolong exposure to the OSW-1 compound has been reported to lead to apoptosis(200, 201), 
mitochondrial dysfunction(130), and intracellular calcium release(130), which are consistent with 
ORP4 functions(48, 54) and suggests the anti-cancer activity of the OSW-1 compound is through 
ORP4 targeting and degradation rather than OSBP disruption. 
Since knockdown of ORP4 was shown to cause cell growth arrest in multiple cells that 
were used in the initial experiment(17), continual treatment with OSW-1 compound was not 
desirable. Our results indicated that the degree to which both OSBP and ORP4 are affected by the 
compound after 24 hours is vastly different (Figure 17A), so we determined if there was a 
differential loss of the proteins over time. We found that treatment with 1 nM of the OSW-1 
compound led to significant loss of OSBP in all cell lines tested at 6 hours, with levels continuing 
to drop up until the 24-hour time point (Figure 17B). In contrast, ORP4 levels are more variable 





Figure 17: Continual OSW-1 compound treatment leads to differential loss of OSBP and 
ORP4. (A) 1 nM of OSW-1 for 24 hours shows significant loss of both OSBP and ORP4. (B) 1 
nM of OSW-1 shows significant loss of OSBP after 4 hrs of treatment with continuing loss up to 
24 hrs while ORP4 does not show significant loss until after 12 hrs. All values are mean ± SD 
(n=3). HCT116 and HEK293 treatments and analysis were done by Mr. Ryan Bensen and Mr. 
Zach Severance. (Full blots in Figure 35, Figure 36 & Figure 37) 
 
2.3.2 Short, non-toxic doses of OSW-1 compound leads to prolonged OSBP loss in multiple cell 
lines up to 72 hours after compound has been removed 
Following up on the differential loss of OSBP over ORP4 (Figure 17B), we determined 
the persistence of OSBP loss after 6 hours of OSW-1 compound treatment, which led to an 
unexpected discovery. Initial results showed that 6-hour treatment followed by removal of the 
compound led to lower OSBP protein levels with diminishing signal up to 4 hours post removal at 
which point OSBP protein was below 10% of the DMSO control in HEK293 cells (Figure 39A). 
A more prolonged recovery time tracking experiment (0-24 hours post compound removal) 
showed no recovery of the protein (Figure 39B). To rule out any possibility of remaining OSW-1 
compound, a standard procedure was implemented which is termed washout experiments. In the 
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OSW-1 compound washout experiments: 1) media containing OSW-1 compound is added to cells; 
2) at the specified time, the compound-containing media is removed; 3) the cells are gently washed 
three times in complete media to remove any residual OSW-1 compound; and, 4) the cells are 
reincubated and recover from treatment in compound-free media for the indicated period of times 
post-washout (pWO). Using the OSW-1 washout experiments, we found that 1 nM OSW-1 
compound treatment for 6 hours followed by washout led to 90% reduced OSBP levels for multiple 
days (48-72 hrs) after the compound has been removed in multiple cell lines (Figure 18). In 
contrast, the taxol control treatment had no effect on OSBP protein levels (Figure 18).  
 
Figure 18: Short, non-lethal doses of OSW-1 compound leads to prolonged OSBP loss in 
multiple cell lines up to 72 hours after compound has been removed. All cells tested were 
subjected to 1 nM OSW-1 compound, 1 nM Taxol, or DMSO treatment for 6 hours followed by 
washout and lysed at the indicated pWO time. All values are mean ± SD (n=3). HCT116 and 
HEK293 treatments and analysis were done by Mr. Ryan Bensen and Mr. Zachary Severance. 
(Full blots in Figure 38) 
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2.3.3 Loss of OSBP due to OSW-1 washout is not an artifact 
To confirm that OSBP levels were reduced due to cellular mechanisms, we performed a 
series of experiments to eliminate possible artifacts. First, to make sure that loss of OSBP was not 
due to the freeze thaw (AC) lysis procedure, a chemical lysis with mammalian protein extraction 
reagent (Mper) lysis method was used due to its ability to extract ~25% more protein(202) (Figure 
19A). Both lysis methods confirm the loss of OSBP to similar levels in multiple cell lines. We 
utilized multiple antibodies recognizing different OSBP epitopes to confirm the reduction of OSBP 
(Figure 40). The two additional antibodies used show similar OSBP levels in both DMSO and 
OSW-1 compound treated cells. In addition to Western blot confirmation of OSBP loss, we 
employed bottom-up proteomic mass spectrometry to confirm the reduction of OSBP levels. A 
two-dimensional low/high pH HPLC separation of the trypsin-digested lysates was employed to 
allow for the detection of the low abundance OSBP-peptides without enrichment or 
purification(203). The proteomic mass spectrometry analysis was done by the research group of 
Professor Si Wu in the Department of Chemistry and Biochemistry at the University of Oklahoma. 
This analysis shows a significant reduction in the detected OSBP peptides in the OSW-1 washout 
cells as compared to DMSO washout cells (Figure 19B & C), which confirms the reduction of 
OSBP levels detected by Western blotting (Figure 18). 
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Figure 19: Loss of OSBP due to OSW-1 compound washout is not an artifact. (A) Freeze thaw 
(AC) and mammalian protein extraction reagent (Mper) lysis methods show similar OSBP loss in 
1 nM OSW-1 compound washout treated cells 24 hours pWO as quantified by Western blot 
analysis. (B) Bottom up proteomic mass spectrometry analysis of vehicle control or 1 nM OSW-1 
compound treated for 6 hours followed by washout and a 24-hour recovery period. (C) Shows loss 
of detectable OSBP peptide (i.e. peak with retention time of 39.33 min) in HEK293 washout cells 
as compared vehicle control. (B) and (C) lysates and analysis performed by Mr. Zachary Severance 
and Ms. Hongyan Ma; Ms. Ma is a graduate student in the lab of Dr. Si Wu, Department of 
Chemistry and Biochemistry, Univ. of Oklahoma. (Full blots in Figure 41). The author had no 
contribution to producing the bottom up MS results. 
 
2.3.4 Cellular localization of OSBP confirms OSBP loss in vivo during washout recovery. 
To verify the loss of OSBP other than by Western blotting, we utilized 
immunofluorescence microscopy in HCT116 cells. OSBP is predominately located at ER/Golgi 
membrane contact sites(35, 36, 128, 204) Cellular treatment with the OSW-1 compound is known 
to alter the OSBP localization in the cell(46). The imagining experiments used the OSBP antibody 
and an antibody recognizing the trans Golgi marker TGN46, as well as a nuclear stain. Both 
continual treatment and washout treatment showed reduced OSBP levels (Figure 20). DMSO 
treated cells showed OSBP localized to the TGN46 marker in a perinuclear fashion and treatment 
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with OSW-1 compound led to relocalization into a punctate cluster (Figure 20). Continual 
treatment with the OSW-1 compound showed OSBP clustering within 2 hours followed by 
diminishing OSBP signal. Very little OSBP signal is evident at 24 hours (Figure 20A), which is 
consistent with the Western blot OSBP levels upon continuous OSW-1 compound treatment 
(Figure 17B). The TGN46 Golgi signal also decreased and became dissociated from some of the 
OSBP starting at 12 hours of continuous OSW-1 compound treatment. Similarly, the OSW-1 
compound washout cells showed a similar clustering pattern at 0-hour post-washout recovery (6-
hour straight treatment) (Figure 20B). The OSBP signal remains substantially reduced 24 hours 
post-washout. The localization of the TGN46 signal changed from the DMSO-treated pattern at 0-
4 hours post-washout, but the TGN46 signal returns to a perinuclear pattern staining starting at 8 
hours post-washout. The low OSBP signal also returns to a perinuclear colocalization pattern with 
TGN46 at 12 and 24 hours post compound removal (Figure 20B). These results suggest that the 
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Golgi has returned to a normal localization pattern post-washout of the OSW-1 compound
  
Figure 20: Cellular localization of OSBP confirms OSBP loss in vivo during washout 
recovery. (A) Continuous 1 nM OSW-1 compound treatment in HCT116 cells shows localization 
of OSBP to the Golgi followed by loss of both OSBP and Golgi signals. (B) OSW-1 washout 
treatment (i.e., 1 nM for 6 hours, then recovery post-washout for the indicated times) reduces 
OSBP and Golgi signals but the reduced OSBP and Golgi signal localization patterns are similar 
to DMSO-treated by 24-hour recovery. 
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2.3.5 OSW-1 compound washout cells show no signs of cytotoxicity, cell growth arrest, or 
morphological changes. 
The effect of short-term, transient and low dose OSW-1 treatment on cellular viability and 
morphology was determined. The cellular viability of washout cells was tracked using Trypan blue 
staining over the 72-hour recovery course in HCT116 and HEK293 cell lines (Figure 21A). The 
viability of both cell lines showed no change in comparison to vehicle control washout cells. As a 
second confirmation that the washout cells were not affected by long-term OSBP loss, we utilized 
cellular viability imaging using Calcein AM and Hoechst 33342 staining of HEK293 cells (Figure 
21B). There was no apparent cytotoxicity based on the staining patterns and overall cellular 
growth/morphology between DMSO and OSW-1 compound washout cells was similar. In 
contrast, continual treatment of OSW-1 compound over 72 hours showed apparent cytotoxicity 
after 24 hours of treatment with most of the cells dead by the 72-hour mark (Figure 42A). This 
evidence shows that cells continue to function normally despite long-term OSBP loss and that 
OSBP loss is sustained through 2-3 rounds of cellular division. 
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Figure 21: OSW-1 compound washout cells show no signs of cytotoxicity, cell growth arrest, 
or morphological changes. (A) Trypan blue staining of HEK293 and HCT116 0-72 hours pWO 
of 1 nM OSW-1, 1 nM taxol, or DMSO. (B) Calcein AM and Hoechst 33342 staining of 0-72 
pWO of 1 nM OSW-1 or DMSO in HEK293 cells using Operetta High-Content Imaging System. 
 
2.3.6 The long-term reduction of OSBP levels upon OSW-1 compound washout treatment occurs 
in multiple cell lines and with as little as 1 hour of exposure. 
The effect on OSBP levels of OSW-1 washout treatment in other human cultured cell lines 
from various tissue types was determined. The cancer cell lines (HCT116, HeLa, K562, and MCF-
7) as well as the normal cell lines (HEK293 and MRC5) tested showed significant loss of OSBP 
signal after 24 hours pWO with an initial 1 nM, 6-hour OSW-1 compound treatment (Figure 22A). 
The cell line that showed the least sensitivity to the washout, but was still significantly reduced, 
was the diploid lung-fibroblast MRC5 line which has a finite passaging of 42-46 replications(205). 
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Interestingly, no ORP4 signal could be detected by Western blotting in the MRC5 cell line, which 
could explain the finite replication ability of these cells. 
Having established the OSBP reduction upon OSW-1 compound treatment in multiple cell 
lines, the minimal time and concentration of OSW-1 washout treatment to induce the OSBP 
reduction was determined. A 1 hour treatment of 1 nM OSW-1 compound, followed by the 
compound’s washout removal, was sufficient to induce significant OSBP reduction 24 hours pWO 
in all cell lines tested (Figure 22B). Following this result, the time was reduced to check the 
exposure on the minute scale. We found that 45 minutes of exposure with 1 nM OSW-1 compound 
led to significant reduction of OSBP 24 hours pWO in all cell lines tested (Figure 22C). 
Additionally, 15 minute exposure in two of the cell lines was sufficient to cause ~50% reduction 
of OSBP 24 hours pWO. Additionally, compound concentration was tested at 6 hours of exposure 
and it was determined that 0.5 nM concentration could significantly lower OSBP levels similar to 
1 nM, but lower concentrations failed to induce the response (Figure 46). These experiments show 
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that the OSW-1 compound “washout effect” is triggered by very low and very brief OSW-1 
compound exposures. 
Figure 22: The long-term reduction of OSBP levels upon OSW-1 compound washout 
treatment occurs in multiple cell lines and with as little as 1 hour of exposure. (A) All cell 
lines tested with 1 nM OSW-1 compound followed by 24-hour recovery show significant OSBP 
loss. (B&C) 1 nM treatment of OSW-1 for the indicated times, followed by 24-hour recovery 
shows significant loss of OSBP with as little as 30 minutes of treatment in various cell lines. 
HCT116, HEK293 and HeLa treatments and analysis were done by Mr. Ryan Bensen and Mr. 
Zachary Severance. (Full blots in Figure 43, Figure 44 & Figure 45). 
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2.3.7 OSW-1 compound washout prolonged reduction of OSBP is not due to residual compound 
We reasoned that the observed OSBP reduction caused by the OSW-1 compound washout 
was not likely caused by residual compound present in the cell media or cell culture plastic. 
However, to verify this we utilized the suspension cell line K562, following OSW-1 treatment, 
allowed for complete transfer of cells to new plasticware devoid of any OSW-1 as part of the 
washout condition. Further, to determine if the OSW-1 compound remained in cells at biologically 
relevant concentrations following the washout condition, we used two complementary mass 
spectrometry analytical techniques to measure intracellular OSW-1 levels. We first used 
quantitative LCMS measurements using a deuterated OSW-1 compound as an internal standard to 
measure OSW-1 compound from HCT116 cell lysates (Figure 23A & Figure 47). The 
intracellular soluble non-protein bound OSW-1 compound concentration of HCT116 cells treated 
for 1 hr with 100 nM of the compound was 1.74 ± 0.74 µM (Figure 23C). Post-washout, followed 
by a 24-hour recovery, the intracellular OSW-1 compound concentration was below the 
measurable threshold of ~100 pM (Figure 23A & Figure 48). 
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Figure 23: Mass spectrometry quantification shows intracellular OSW-1 concentrations are 
reduced to non-detectable levels 24 hours post washout (pWO). (A) Liquid Chromatography 
Mass Spectrometry (LCMS) quantification of OSW-1 at 0 and 24 hours pWO of a 100 nM 
treatment of HCT116 cells for 1 hour.  50 nM of the deuterated OSW-1 analog is used as an internal 
standard to allow for LCMS compound quantification. (B) Single Cell Mass Spectrometry 
quantification (SCMS) spectra of intracellular OSW-1 detection in HCT116 cells following the 1 
hour, 100 nM OSW-1 treatment at 0 and 24 hours pWO. A minimum of 30 cells were analyzed 
for each of the experimental conditions. (C) LCMS single cell intracellular quantification of the 
amount of OSW-1 (moles) and estimated concentration utilizing the total cell count and averaged 
cellular volume. Average of three independent biological replicates reported (n=3). NQ= Not 
Quantifiable. Experiments and analysis were conducted by Mr. Ryan Bensen and Ms. Shawna 
Standke. The author had no contribution to producing the results. 
 
Single cell mass spectrometry (SCMS) is a method that can quantify intracellular concentrations 
of compounds in a similar manner as LCMS but does not require any sample preparation that could 
lead to loss of analytes due to cell lysis(206–209). Using this semi-quantitative technique, we 
confirmed the loss of detectable intracellular OSW-1 compound after the washout conditions 
(Figure 23B, Figure 49 & Figure 50). These results showed that no OSW-1 compound is present 





experiments (Figure 19 & Figure 22), but that a persistent cellular mechanism triggered by OSW-
1 treatment is responsible for the long-term reduction of OSBP levels.  
2.3.8 OSW-1 compound washout induces prophylactic antiviral response to two clinical isolates 
of Enteroviruses. 
As stated before, OSBP is required for the cellular replication of viruses belonging to the 
Enterovirus genus, which includes many human pathogens (1.4.1.2 Enteroviruses). OSW-1, as 
well as other OSBP binding compounds, has been shown to inhibit the replication of multiple 
Enterovirus viruses in cells (1.5 ORPphillins and OSBP/ORP4). Consistent with published 
results, continuous treatment of OSW-1 compound inhibits the viral replication of two clinical 
isolates of pathogenic Enterovirus viruses, Coxsackievirus A9 and Echo2, in HeLa cells in a 
concentration-dependent manner (Figure 24A). Continual OSW-1 compound treatment reduced 
the viral titer of 10-hour viral infection in HeLa cells approximately ~10,000 fold (Figure 24A). 
HeLa cells subjected to a 6-hour OSW-1 compound treatment followed by the washout protocol 
and a 24 hour recovery in compound-free media showed a reduction of viral titers of approximately 
100-fold for the Echo2 virus and ~1000-fold for the Coxsackievirus 9A virus (Figure 24B). Based 
on the quantitative mass spectrometry of intracellular OSW-1 compound levels 24 hours pWO 
(Figure 23), this observed prophylactic anti-viral activity in the OSW-1 compound washout 
experiment is not likely due to residual OSW-1 compound. Instead, the anti-viral activity is likely 
due to a sustained reduction of OSBP levels pWO as seen in HeLa cells where 1 nM OSW-1 
compound washout reduced OSBP levels by ~90% 24 hours pWO (Figure 22A).  
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Figure 24: OSW-1 compound washout induces prophylactic antiviral response to two clinical 
isolates of Enteroviruses. (A)Viral titers of infected HeLa cells incubated in the presence of the 
OSW-1 compound. Cells were treated with the indicated concentrations of OSW-1 compound for 
6 hours, followed by viral infection for 30 min (MOI of 1.0), followed by re-incubation for 10 
hours with OSW-1 compound (B) Viral titers in OSW-1 compound washout HeLa cells. Cell were 
treated with the indicated concentrations of OSW-1 compound for 6 hours, compound was 
removed, cells were allowed to recovery for 24 hours in compound-free media. Then, cells were 
infected for 30 min with virus (M.O.I.=1.0) followed by 10-hour incubation in compound-free 
media. All viral results were collected by Dr. Earl Blewett. The author had no contribution to 




The results show that the OSW-1 compound cellular treatment induces the reduction of both 
OSBP and ORP4 in a similar manner, but on different time frames and to different amounts 
(Figure 17). OSBP is degraded much faster and to a much more pronounced degree than ORP4; 
ORP4 levels only decrease after 24 hours of continuous treatment (Figure 17B). Importantly, the 
reduction of ORP4 levels at 24 with 1 nM continuous OSW-1 treatment is consistent with observed 
cytotoxicity in  HEK293 cells (Figure 42A). Given that we and others show loss of OSBP does 
not result in cytotoxicity(46) (Figure 21), these results would suggest that OSBP could act to 
absorb the OSW-1 compound preventing the compound from interacting with ORP4. As the OSBP 
levels rapidly drop due to OSW-1 compound, the compound could then interact with ORP4 
causing the cytotoxicity. 
Our results show that short non-toxic cellular treatment with the OSW-1 compound followed 
by removal of the compound from the cells, leads to a sustained loss of OSBP (~90%) lasting 48-
72 hours after the compound treatment stopped. This OSBP reduction upon the OSW-1 washout 
happens in multiple cell lines and persists through multiple cell divisions (Figure 19). The OSW-
1 compound washout cells do not show any signs of growth arrest, cytotoxicity or changes in 
cellular morphology (Figure 21). The OSW-1 compound interacts with OSBP and ORP4 with 
comparable affinities, as measured through in vitro competitive binding of 25-hydroxycholsterol 
(Figure 51). ORP4 protein levels do not change significantly upon the OSW-1 washout conditions, 
and this is consistent with the lack of induced cytotoxicity (Figure 42B). Additionally, 
morphology of the Golgi network returns to a normal pattern 12 hours post-washout during the 
washout recovery and the trans Golgi network appears to recover 12 hours pWO ( Figure 20). 
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The lack of cytotoxicity in the OSW-1 compound after washout from cells, despite the 
sustained loss of OSBP suggests either OSBP is not necessary in cellular growth or that there is a 
compensatory mechanism that possibly works through the functional redundancy of the 
OSBP/ORP family. In contrast to this, OSBP function is necessary for the replication of various 
human pathogens across different viral families (1.4.1 OSBP Function in Virus Replication). 
OSW-1 treatment has been shown to cause inhibition of Enterovirus replication(81, 82) and we 
have shown that continuous treatment of cells with OSW-1 inhibits two clinical isolates of 
Enteroviruses (Figure 24A). We also show that the OSW-1 compound “washout effect” induces 
a prophylactic antiviral response to two clinically isolated Enterovirus species (Figure 24B). This 
is the first time a broad-spectrum, prophylactic anti-viral response is reported through targeting a 
host protein. This suggests that OSW-1-derived compounds triggering the long-term reduction of 
OSBP levels is a discovery that has clear therapeutic potential.  
2.5 Conclusion 
The discovery that brief, transient OSW-1 compound treatment induces a long-term 
reduction of OSBP levels is a novel and potentially significant discovery. The compound induced 
OSBP reduction prevents Enterovirus replication in cells. This novel prophylactic, broad-spectrum 
anti-viral activity presents a new approach to potentially preventing and treating infections against 
a wide range of important human viral pathogens that currently have no approved preventable or 
direct treatment. New classes of OSW-1-derived compounds capable of selectively binding OSBP 
and not ORP4 would be critical chemical probes in defining the regulation and anti-viral 
therapeutic potential of compound-induced OSBP repression. Such OSBP-specific, noncytotoxic, 
small molecule effectors could be potentially developed to inhibit a broad spectrum of severe 
human pathogenic viruses that currently cannot be prevented or directly treated. 
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2.6 Methods 
2.6.1 Cell Lines and Viruses 
HEK293 STF (ATCC CRL-3249) and HeLa (ATCC CCL-2) were cultured in DMEM 
(Thermo 11995073) supplemented with 10% Hyclone (Fisher Sci SH3006603) and 1% penicillin-
streptomycin (Thermo 15140122). HCT116 (ATCC CCL-247) was cultured in McCoy 5A media 
(Thermo 16600108) supplemented with 10% Hyclone and 1% penicillin streptomycin. K-562 
(ATCC CCL-243) was cultured in RPMI 1640 (Thermo 22400105) media supplemented with 10% 
Hyclone and 1% penicillin streptomycin. MCF-7 cells were a gift from R. Cichewicz (University 
of Oklahoma, Norman) and cultured in MEM (Thermo 11095114) media 10% Hyclone, 1% 
penicillin streptomycin and 0.2 mg/mL insulin (A11382II). MRC-5 cells were a gift from E. 
Blewett (Oklahoma State University- Center for Health Sciences, Tulsa) and cultured in MEM 
media supplemented with 10% Hyclone and 1% penicillin streptomycin. RD, 
(rhabdomyosarcoma) cells (ATCC-CCL-136) were cultured in DMEM (Fisher Sci 
SH30081.0) with 10% FBS (Atlanta Biological S11550) and 1% penicillin-streptomycin (Gibco 
15140-122). Coxsackievirus A9 (strain CoxA9-01) and Echovirus 2 (strain Echo2-01) were 
obtained from the Oklahoma State Department of Health Laboratory. They are clinical isolates, 
obtained from OK residents and typed by the OK State Department of Health and/or the Center 
for Disease Control and Prevention. All other identifiers have been stripped off. These viruses 
were passaged twice in RD cells, aliquoted in 1.0 mL amounts and stored in complete medium at 
-80 ⁰C. Each virus was titered on RD cells using a 50% tissue culture infective dose (TCID-50) 
assay(210). To allow a multiplicity of infection (M.O.I.) to be determined, a conversion factor of 
0.7 was used to change TCID-50 to plaque forming units (pfu)/ml. 
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2.6.2 General Cell Culture 
All mammalian cell lines were cultured at 37 ºC in 5% CO2. All handling of the 
mammalian cell culture was performed in a standard tissue culture hood using standard aseptic 
technique. Cell lines were cultured in the complete media described above. Cell culture stocks 
were aliquoted in complete media with 10% DMSO in 2 mL cryogenic vials (Corning 430659) 
and stored in liquid nitrogen vapor phase. Before beginning a new culture, the freezer stocks were 
thawed, diluted in 9 mL complete media and plated in Nunclon Delta 10 cm3 dishes (VWR 
10171744) or T25 flask (CellStar 690160) for 
suspension cell lines. After allowing ~16 hours for the revived cells to attach, the DMSO 
containing media was replaced with DMSO free complete media. All revived cultures were split 
at least twice prior to use in an experiment. Cell cultures were restarted approximately every 3-4 
weeks. All cell based experiments reported used multiple restarted cell cultures in the independent 
experiments that make up the replicate results. For experiments, cell cultures were used with a 
confluency of ~70%. The cell cultures were not allowed to ever become superconfluent, and the 
cellular morphology and proliferation rate of the cell culture was carefully tracked to identify any 
abnormalities; any cell culture showing the abnormalities were discarded and the cell line restarted 
from frozen stocks. For experiments, cells were allowed to recover from splitting and replating a 
minimum of 16 hours prior to the start of an experiment. 
The adherent mammalian cell lines are split every ~3 days with the following general 
procedure: the complete media is removed via aspiration and the cells are gently washed with 5 
mL of 1X PBS. TrypLETM trypsin reagent (2.5 mL for 10 cm2 plate) is added and incubated for 
approximately 10 min at 37 ºC. After 10 mins 7.5 mL of the complete culture media is added to 
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inactivate the TrypLETM reagent. Cells were counted using a TC20™ Automated Cell Counter 
(BioRad), by combining 10 µL of cell solution with 10 µL Trypan Blue stain (Thermo 15250061). 
The K562 leukemia suspension cell line was handled as described for the adherent cell lines 
except for the splitting and seeding procedure. For K562 cells, the cells were centrifuged at 200 x 
g for 5 minutes and the media was aspirated from the cell culture using care so as not to disturb 
the cell pellet and replaced with 10 mL of complete media. The cell pellet was then resuspended 
and diluted to the desired seeding density using complete media. 
2.6.3 OSW-1 Compound 
The OSW-1 compound used was obtained through total synthesis in the Burgett lab or from 
isolation from the natural source. OSW-1 used in the experiments was of >95% purity as 
determined with 1H-NMR and LCMS analysis. Solid OSW-1 compound was dissolved in 
analytical grade DMSO solution to produce 10mM stocks for experimentation. The 10 mM OSW-
1 stock solution was aliquoted into Eppendorf brand 1.5 mL centrifuge tubes; Each individual 10 
mM OSW-1 aliquot was thawed no more than three times. Additional cycles of freeze/thaws 
caused partial loss of OSW-1 compound in the aliquots. 
2.6.4 Cell Lysis 
Cell Lysis Method 1 (AC Freeze/Thaw Lysis): Adherent cells were cultured in Nunclon 
Delta 10 cm3 dishes (VWR 10171744) and lysate preparation began by removing the media, 
washing with 1X PBS, followed by addition of 1 mL PBS and scraping. Cells were collected in a 
1.5 mL Eppendorf brand centrifuge tubes and spun down at 14,000 x g for 45 seconds. Supernatant 
was removed, and the cells were resuspended in 50 µL of AC Lysis buffer (150 mM NaCl, 1.5 
mM MgCl2, 5% glycerol, 0.8% NP40, 1mM DTT, 50 mM HEPES, 25 mM NaF, 1 mM Na3PO4) 
with 3X HALT/EDTA protease inhibitor (Thermo 78438) and 0.2 mM 
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phenylmethanesulfonylfluoride (Goldbio). Cell lysis was performed by freezing in liquid nitrogen 
and thawing in a 37°C bead bath three times, followed by a 14,000 x g centrifugation for 15 
minutes. Supernatant was transferred to a new tube and a portion was taken for protein 
quantification using a Bradford assay (Bio-Rad Protein Assay Dye Reagent Concentrate 
#5000006, BSA-Santa Cruz sc-2323). After protein quantification, the lysates were diluted to the 
desired concentration using AC lysis buffer and a final concentration of 1X Laemmli buffer (1 M 
Tris pH 6.8, 8% SDS, 40% glycerol, 20% β-mercaptoethanol, and 0.2% bromophenol blue), 
followed by dry bath heating at 95°C for 10 minutes. 
Adherent cells cultured on 6-well plates (Greiner 657160) were lysed by removing media, washed 
with 1X PBS, followed by adding 0.5 mL TrypLETM Express (Gibco 12605010) and incubated at 
37°C for 5 minutes. TrypLETM was neutralized using 0.5 mL of media and cells were then 
transferred to a 1.5 mL Eppendorf tube spun down at 14,000 x g for 45 seconds. Supernatant was 
removed, and 1 mL of PBS was added to wash the cells. Cells were spun down at 14,000 x g for 
45 seconds, supernatant was removed, and the cells were resuspended in 50 µL of AC lysis buffer. 
Freeze/thaw method was continued as described above. 
For suspension cell lines, cells were centrifuged at 200 x g for 5 minutes and the supernatant 
removed. Cell pellet was resuspended in 1 mL of PBS and spun down at 14,000 x g for 45 seconds, 
supernatant was removed, and cells were resuspended in 50 µL of AC lysis buffer. Freeze/thaw 
method continued as above. 
Cell Lysis Method 2 (MPER Extraction): Mammalian protein extraction reagent, MPER, 
(Thermo 78501) was used as an alternative lysis method for 10 cm3 dishes. Media was removed 
from the cells, and 5 mL of 1X PBS was added to wash cells. 1 mL of MPER was added to the 
plate and was shaken in a room temperature (Innova 42 incubator) at 250 rpm for 5 minutes. The 
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solution was collected and spun down at 14,000 x g for 10 minutes. Supernatant was placed in a 
new tube and the protein concentration and sample preparation was conducted as described above. 
2.6.5 Western Blotting 
SDS-PAGE gels (8.5%) containing 25 µg of total protein per well were transferred to 0.45 µm 
nitrocellulose (Bio-Rad 1620115) using constant voltage (100V) for 1 hour at 4°C in 1X transfer 
buffer with 10% ethanol. After transferring, the nitrocellulose membrane was blocked with 5% 
milk 1X TBST at room temperature for 30 minutes. The membranes were then washed three times, 
five minutes each, with 1X TBST. Primary incubation with antibodies was done overnight at 4°C. 
After primary incubation, the blots were washed five times, five minutes each, with 1X TBST and 
then incubated in secondary antibody in 1% milk TBST for 30 minutes at room temperature. After 
secondary antibody incubation, the blots were washed five times, five minutes each, with 1X TBST 
and then once with 1X TBS for ten minutes. TBS was removed, and the blots were incubated in 
ClarityTM Western ECL substrate (Bio-Rad 1705061) and imaged on the Bio-Rad ChemiDocTM 
Touch Imaging System using the chemiluminescence setting with 2x2 binning. Ladder images 
were taken using the colorimetric setting. After development, the membranes were washed with 
1X TBST twice for five minutes each. 1:1000 β-actin HRP (Santa Cruz sc-47778 HRP) in 1% milk 
TBST was added and incubated for 1.5 hr at room temperature. Developing occurred the same as 
after secondary antibody incubation. Primary antibodies used were 1:500 OSBP A-5 (Santa Cruz 
sc-365771), 1:1000 OSBP2 B-1 (Santa Cruz sc-365922), 1:1000 OSBP1 1F2 (Novus NBP2-
00935), and 1:1000 OSBP1 (Novus NBP2-47343). Secondary antibodies used were 1:3000 goat 
anti-mouse IgG1-HRP (Santa Cruz sc-2060) and 1:3000 goat anti-rabbit IgG-HRP (Santa Cruz sc-
2004). 
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2.6.6 Washout Experiments 
Cells were treated with 1 nM OSW-1, 1 nM Taxol, or DMSO media for 6 hours or the indicated 
time period. Media was removed, and the cells were gently washed with 5 mL of complete media 
3 times and then 10 mL of fresh, OSW-1 compound free media was added back to the cells. 
Compound removal and washing for K562 cells utilized were centrifuged at 200 x g for 5 minutes 
for each step. The cells were then allowed to recover for the indicated times (0-72 hours) and were 
lysed as described above and analyzed by Western blot. 
2.6.7 Immunofluorescence 
50,000 cells were seeded onto sterile 18 mm cover slips in 12 well plates for treatments lasting (0-
24 hours) or 25,000 cells for longer treatment. The cells rested for 24 hours before treatment to 
ensure attachment of the cells. Once treatments were completed media was aspirated and cells 
were washed with warm 1X PBS. PBS was removed and 0.5 mL of freshly prepared 4% 
paraformaldehyde in PBS was added. Coverslips were at 37°C for 20 mins and then the 
paraformaldehyde was removed followed by three 1X PBS washes. Permeabilization of the cells 
was done with 0.5 mL of 0.5% Triton X-100 in PBS at room temperature for 10 minutes. 1X PBS 
was used to wash the cells three times. Image-iT FX signal enhancer (Thermo I36933) was added 
onto the cover slips and incubate at room temperature for 30 minutes followed by three 1X PBS 
washes. Coverslips were blocked with 0.5 mL of 1% BSA in PBS at room temperature for 30 
minutes followed by three washes with 1X PBS. Primary antibody was added, and the slips were 
incubated overnight at 4°C. The primary antibody solution was removed and washed slips three 
times with 1X PBS. Secondary antibody solution was incubated in darkness at room temperature 
for 1 hour. The secondary antibody solution was removed and washed three times with 1% BSA-
PBS, three times with 1X PBS, and then soaked the cover slip in 300 nM DAPI (Thermo D1306) 
66 
solution for 10 minutes Mounted the slips onto glass slides using VECTASHEILD HardSet 
Antifade mounting media (VECTOR labs H-1400). Stored slides at -20°C until imaging was 
conducted. Primary antibodies used were 1:100 OSBP1 1F2 (Novus NBP2-00935) and 1:500 
TGN46 (Novus NBP1-49643). Secondary antibodies used were 1:500 goat anti-mouse IgG H&L 
Alexa Fluor® 488 (Abcam ab150113) and donkey anti-rabbit IgG H&L Alexa Fluor® 594 
(Abcam ab150076). Imaging was done with a Lecia SP8 using a 63x objective with 2x digital 
zoom. Images were analyzed with ImageJ software. 
2.6.8 Trypan Blue Staining 
HEK293 and HCT116 cells were seeded out at 0.85 x 105 cells/mL into 10 cm3 dishes and left to 
recover for 20 hours. Cells were treated with 1 nM OSW-1, 1 nM Taxol, or DMSO for 6 hours, 
followed by washout procedure and recovery for 0-72 hours. After recovery time, cells were 
washed with 1X PBS and then incubated in 2.5 mL TrypLETM for 5 minutes at 37°C. Reaction 
was neutralized using 7.5 mL of fresh media and cells were counted and viability analyzed on a 
TC20™ Automated Cell Counter (BioRad) by combining 10 µL of cell solution with 10 µL Trypan 
Blue stain (Thermo 15250061). 
2.6.9 Calcein AM and Hoechst Staining 
HEK293 cells were seeded out at 10,000 cells per well into a 24-well plate and left to recover for 
20 hrs. Half the plate of cells was treated with 1 nM OSW-1, 1 nM Taxol, or DMSO for 6 hours, 
followed by washout while the other half was treated with the same concentration continuously. 
Washout and continual time points were 0, 24, 48, and 72 hours, with the cells being treated on 
subsequent days, therefore, all time points ended collectively. Once the treatments were finished, 
the media was removed and a solution of 5 µM Calcein AM (Thermo C1430) and 5.5 mg/mL 
Hoechst 33342 (Thermo H1399) was added to the cells and incubated at 37°C for 1 hour. Plate 
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was imaged using an Operetta High-Content Imaging System (PerkinElmer) using brightfield, 488, 
and Hoechst settings. 
2.6.10 Intracellular OSW-1 Quantification Using LC-MS and Single Cell MS Methods 
nano-UPLC/MS: HCT-116 cells (1.5x105) were seeded in a 6-well plate. Upon 60% 
confluency, cell lysate was created following a 1 hour treatment of 100 nM OSW-1, with or 
without a 24 hour post wash recovery. Trypsin (0.5 mL) was used to detach the cells, with 
additional McCoy’s media (0.5 mL) to stop digestion. Cell count was performed using a Bio-Rad 
TC20TM Automated Cell Counter with trypan blue viability staining. Cells were spun at 500 x g 
for 5 min followed by a 1-mL PBS wash. The cell pellet was lysed using 1 mL of 50 nM d-OSW-
1 dissolved in cold acetonitrile and methanol (1:1) with brief vortexing on ice for 10 min. The cell 
pellet was spun at 15000 x g at 4°C for 15 min. The supernatant was transferred to a new tube and 
dried using a speed vacuum (Savant SPD11V, Thermo Scientific) at 70°C. Prior to analysis, cells 
are resuspended in 150 µL of ACN: H2O (1:10). Analysis was performed using a Waters 
nanoAQUITY BEH C-18 column (100 µm x 100 mm, 1.7 µm) coupled with a mass spectrometer 
(Thermo LTQ Orbitrap XL, Waltham, MA) using a flow rate of 0.3 uL/min. Mobile phase A is 
ACN with 0.1% formic acid, and mobile phase B is H2O with 0.1% formic acid. The time/%A are 
as follows: 0/0, 1/50, 2/100, 3/100, and 4/0 for a total runtime of 5 minutes. Treatment of cells was 
done by Mr. Ryan Bensen and analysis of sample was done by Ms. Shawna Standke of Dr. Zhibo 
Yang’s lab in the Department of Chemistry and Biochemistry, Univ. of Oklahoma.  
2.6.11 Single Cell Mass Spectrometry 
HCT-116 cells (1.5x105) were seeded on to a glass microchip (18 mm diameter) with 
chemically-etched microwells (55 µm diameter; 25 µm deep) placed into each well of a 6-well 
plate. Upon 60% cell confluency, cells were treated as described for nano-UPLC/MS.  Following 
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treatment, the microchip was washed with 5 mL of FBS-free McCoy’s media and placed on an X, 
Y, Z-translational stage for quantification. MS analysis was performed as previously 
described(206). Briefly, singleprobes were coupled to the mass spectrometer by using a flexible 
arm clamp to position the nano-ESI emitter in front of the inlet. The solvent-providing capillary 
was connected to the solvent through the conductive union. For quantification, 50 nM d-OSW-1 
was added into the solvent. High voltage (~4.5 kV) was used for SCMS experiments in the positive 
ion mode with a mass resolution (m/∆m) of 60,000. A flow rate of ~5 nL/s was used (the actual 
flowrate is optimized for each Single-probe). Data was collected using Xcaliber software and 
exported into Excel for analysis. Treatment of cells was done by Mr. Ryan Bensen and analysis of 
sample was done by Ms. Shawna Standke of Dr. Zhibo Yang’s lab in the Department of Chemistry 
and Biochemistry, Univ. of Oklahoma.  
2.6.12 Mass Spec label-free 2D OSBP quantification 
The first-dimension high-pH (pH=10) separation was performed on a Thermo Accela HPLC 
system (Thermo Scientific, Hanover Park, IL) with an ACQUITY UPLC BEH300 C18 column 
(50mm, Waters, Milford, MA, USA). The mobile phase A (MPA) was 20 mM ammonium formate 
in water and the mobile phase B (MPB) was 20 mM ammonium formate in acetonitrile. The mobile 
phases were adjusted to pH 10. A 60-min gradient from 3% to 70% (3% to 10% in a minute) 
mobile phase B was applied for peptide separation, and 60 fractions were collected (one minute 
per fraction). Fraction concatenation was performed following Yang’s paper(213). A total of 12 
fractions were obtained for the second-dimension low-pH LC-MS/MS analysis. Cell treatments 
were performed by Mr. Zachary Sevarance and the analysis was performed by Ms. Hongyan Ma 
of Dr. Si Wu’s lab in the Department of Chemistry and Biochemistry, Univ. of Oklahoma.  
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2.6.13 Anti-Viral Experiments 
HeLa cells were grown to <75% confluency (healthy log phase cells) in complete media, 
DMEM (Hyclone SH30081.0) with 10% FBS (Atlanta Biological S11550) and 1% penicillin-
streptomycin (Gibco 15140-122). For experiments, cells were trypsinized, counted using a 
hemocytometer and seeded into 20 wells of two 24-well trays (Falcon 3047) with 2.0 x 105 cells 
per well, in 1.0 mL complete media. Each treatment is performed using quadruplicate wells (n=4) 
and each virus was on a separate plate. After seeding, cells were incubated 20 hours at 37 ºC, 5% 
CO2, at which point cells have grown to a near confluent monolayer. 
For the OSW-1 compound continual treatment experiments, (Figure 24A), the media was 
gently removed from each well, and 1mL of media was added with the desired OSW1-compound 
concentration to each well, without disturbing the cells. Cells were incubated for 6 hours, after 
which time the media was removed and cells were gently washed three times with 1.0 mL of FBS-
free DMEM media. After the media was removed, CoxA9-01 or Echo2-01 viruses, diluted in 
serum-free DMEM with a M.O.I. of 1.0 was added to the culture. The 2.0 x 105 cells per well was 
assumed to double during incubation so 4.0 x 105 pfu/well of virus was used for an M.O.I. of 1.0.  
The virus and cells were incubated for 30 minutes at 37 ºC 5% CO2. Then, the virus inoculum was 
removed, and the culture washed one time with 1.0 mL of serum-free media per well. Then, 1.0 
mL of complete media with the indicated concentration of OSW-1 was added to the well, and the 
infected cells were then incubated for 10 hours at 37 ºC, 5% CO2. After 10 hours the plate was 
stored at -80 ⁰C until the TCID-50 titration. The experiment reported in the Figure 24A was 
repeated independently three times. 
For the OSW-1 compound washout treatment experiments, (Figure 24B), cells were 
seeded as above. After 20 hours incubation the media was gently removed from each well, and 
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1mL of media was added with the desired OSW-1 compound concentration to each well, without 
disturbing the cells. Cells were incubated for 6 hours, after which time the media was removed 
and cells were gently washed three times with 1.0 mL of FBS-free DMEM media. This was 
replaced with complete media and cells allowed to incubate for 20 hours. After the media was 
removed, CoxA9-01 or Echo2-01 viruses, diluted in serum-free DMEM with a M.O.I. of 1.0 was 
added to the culture. The 2.0 x 105 cells per well was assumed to double and double again during 
incubation so 8.0 x 105 pfu/well of virus was used for an M.O.I. of 1.0.  The virus and cells were 
incubated for 30 minutes at 37 ºC 5% CO2. Then, the virus inoculum was removed, and the culture 
washed one time with 1.0 mL of serum-free media per well. Then, 1.0 mL of complete media was 
added to the well, and the infected cells were then incubated for 10 hours at 37 ºC, 5% CO2. After 
10 hours incubation, the plate was stored at -80 ⁰C until processing. Then, the plates were rapidly 
thawed, the cells in media were scrapped from the wells into sterile 1.5 mL centrifuge tubes and 
the suspension then centrifuged at 10,000 g at 4⁰C to produce the virus containing supernatant, 
which is assayed for TCID-50 titration on sub-confluent RD cells. The experiment reported in the 
Figure 24B was repeated independently three times. The TCID-50  titration was performed 
according to the protocol described by Reed et al(210). This experiment was performed 
independently three times to generate the data in the Figure. All viral work was done by Dr. Earl 
Blewett. 
2.6.14 Plasmid and Cloning 
Human OSBP cDNA was obtained in a pOTB7 vector from the Mammalian Gene 
Collection (Thermo). PCR using 5’-GCTAGCATGGCGGCGACGGAG-3’ forward and 
5’AAGCTTGAAAATGTCCGGGCATGAGC-3’ reverse primers amplified a 2.44 kb Nhe 
IHindIII fragment containing a full-length hOSBP cDNA, which was subcloned into pJET1.1 
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(Thermo) and sequence verified. The fragment was then cloned into the pcDNA™ 3.1/myc-His(-
) C mammalian expression vector (Sigma) Nhe I-Hind III doublecut sites. The reverse primer does 
not include an additional nucleotide between HindIII cut site and the last OSBP codon resulting in 
an OSBP-tagless protein. ORP4L was cloned from HCT-116 with cDNA with a NheI forward 
primer 5’-GCTAGCATGGGGAAAGCG-3’ and a HindIII reverse  primer  5’-
AAGCTTCGAAGATGTTGGGGCACATATG-3'. LacZ was PCR amplified from K-12 E. coli 
with NotI forward 5’- GCGGCCGCATGCCCG TCGTTTTA-3’ and BamHI reverse primer 5’-
GGGCGGATCCTTTTTGAC ACCAGACCAA-3’. To generate the proteins expressing tags, the 
MCS of the completed vector was changed through site-directed mutagenesis with a forward 5’-
AAGCTTACGTACGAACAAAAACTCATCTCAGAAGAG3’ and reverse 5’- 
CTCTTCTGAGATGAGTTTTTGTTCGTACGTAAGCTT-3’. The plasmid was expanded in E. 
Coli DH5α, and isolated through miniprep and maxiprep kits (Thermo).  Gene and plasmid MCS 
were sequence verified through Oklahoma Medical Research Foundation (OMRF). This work was 
done by Dr. Juan Nuñez. 
2.6.15 ([3H]-25-OHC) Charcoal/Dextran Binding Assay 
The [3H]-25-OHC binding assay was run according to the protocol outlined in Burgett et 
al(46) by Mr. Zachary Severance and Mr. Ryan Bensen. 
2.6.16 Statistical Analysis  
Results are expressed as mean ± s.d. and are n=3 unless otherwise stated. All statistical 
tests were performed using GraphPad Prism 7.0. Comparison between groups were made by 
using a one-way ANOVA with a follow up Dunnett’s test. The p values are reported using 
GraphPad Prism * values: * is p≤0.05, ** is p≤0.01 *** is p≤0.001, and **** is p≤0.0001. 
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Chapter 3: OSW-1 compound treatment induced OSBP loss occurs 
through an unknown mechanism 
The following chapter is partially taken from the publication in ACS Chemical Biology by the 
author of this dissertation: Persistent, Multi-Generational Reduction of Oxysterol-Binding Protein 
Caused by Compound Treatment Induces Prophylactic Anti-Viral Activity. This was a 
collaborative work that consists of the following authors: Brett L. Roberts, Zachary C. Severance, 
Ryan C. Bensen, Anh T. Le, Naga Rama Kothapalli, Juan I. Nuñez, Hongyan Ma, Si Wu, Shawna 
J. Standke, Zhibo Yang, William J. Reddig, Earl L. Blewett, Anthony W. G. Burgett. 
Mr. Zachary Severance conducted the authophagy experiment in Figure 26 and iTRAQ 
experiment in Figure 28. 
Mr. Ryan Bensen conducted the ALLN experiments in Figure 25. 
Ms. Hongyan Ma conducted the iTRAQ experiment in Figure 28.    
3.1 Abstract 
The natural product OSW-1 causes proteasomal dependent degradation of the oxysterol-
binding proteins OSBP and ORP4. Treatment with short non-toxic doses of OSW-1 compound, 
followed by removal, leads to prolonged reduction of OSBP levels, but not ORP4 (see Chapter 2: 
Persistent Reduction of Oxysterol-binding Protein Caused by Compound Treatment Induces 
Prophylactic Anti-Viral Activity). The compound-triggered repression of OSBP results in a 
prophylactic anti-viral response in cells to clinical isolates of Enteroviruses. The cellular 
mechanism through which short term, lose dose treatment with the OSW-1 compound induced a 
long-term repression of OSBP level in cells is unknown. Here we report that the long-term OSBP 
repression does not occur through a cellular mechanism of OSBP transcription repression, 
proteasomal degradation, or autophagy-induced proteolysis. The half-life of OSBP was 
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determined to be greater than 24 hours, and this result shows the rapid loss of OSBP upon OSW-
1 compound treatment is not due to normal protein turnover. Global analysis of protein levels using 
iTRAQ analysis showed no wide-spread reduction of protein levels similar to the rapid loss of 
OSBP. This result suggests the cellular mechanism triggered by the OSW-1 compound is specific 
to OSBP and not a general effect reducing cellular proteins. Future research is required to identify 
the cellular mechanism through which OSBP levels are repressed upon OSW-1 treatment.  
3.2 Introduction 
The long-term repression of OSBP levels triggered by OSW-1 compound is an unusual 
response of cellular regulation of a protein (see Chapter 2: Persistent Reduction of Oxysterol-
binding Protein Caused by Compound Treatment Induces Prophylactic Anti-Viral Activity). 
Proteins expression levels can be repressed by various cellular mechanism such as transcriptional, 
translational, post-translational or a combination of the three(214, 215). Transcriptional regulation 
can occur from multiple sources within a cell that will lead to the downregulation of mRNA 
production(214, 216). Repression of transcription can occur due to repressor proteins binding to 
silencer DNA sequences that inhibit RNA polymerase from binding the gene, or disrupting 
protein-protein interactions in the transcriptional machinery(216). Transcriptional repression can 
also occur through the methylation of DNA or histones(216). One mechanism of inhibiting 
translation is through microRNA (miRNA) binding to the mRNA which will lead to either 
destruction or sequestration of the mRNA target(217). Protein repression can occur in other forms, 
such as autophagy induction (see section 1.6.4 Autophagy Overview). Post-translational 
modifications such as ubiquitin can target a protein for destruction (see section 1.6.1 Proteasome 
Overview). 
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OSBP is a member of a highly conserved protein family found among all eukaryotes and 
evidence indicates it has roles in cholesterol transport and lipid sensing(1, 5). OSBP transports 
cholesterol from the ER to the Golgi and counter-transports PI4P(35, 36). OSBP can act as a 
sterol/lipid sensor and interact with cellular signaling pathways involved in proliferation and 
transcription(39, 40). The half-life and post-translational regulation of OSBP is not known. OSW-
1 treatment induces a disruption of the trans-Golgi network, presumably through OSBP 
inhibition.OSW-1 treatment has also been shown to induce significant changes in the expression 
profiles of tumor related miRNAs(218). To investigate this mechanism of reduction we utilized 
approaches to determine at which step in the central dogma the reduction was occurring. Our 
results demonstrate that long-term reduction of OSBP does occur through a mRNA transcriptional 
repression, proteasomal degradation, or autophagy-induced proteolysis. 
3.3 Results 
3.3.1 OSW-1 “washout effect” is not due to prolonged proteasomal degradation 
Continual OSW-1 treatment leads to proteasomal dependent degradation of OSBP(46) and 
calpain dependent degradation of the ER stress protein, glucose-regulated protein 78 (GRP78) 
(130). To confirm the previously reported results and to determine if calpains degrade OSBP, we 
utilized various proteasome inhibitors and the calpain inhibitor ALLN (Figure 25A). We found 
that using any proteasome inhibitor or ALLN leads to a significant protection of OSBP in the 
presence of OSW-1, confirming that OSBPs initial degradation is proteasomal dependent. To 
determine if long-term reduction of OSBP was proteasomal dependent, we induced the OSW-1 
“washout effect” in HCT116 cells and allowed recovery for 24 hours to ensure OSBP reduction. 
After the 24 hour recovery, the cells were treated with proteasome inhibitors or ALLN for an 
additional 24 hours and the OSBP proteins levels were compared to washout cells that recovered 
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for 48 hours without additional treatment (Figure 25B). The proteasome inhibitors were not able 
to rescue the OSBP levels at 24 hours post-washout administration (Figure 25B). Only bortezomib 
was able to partially recover OSBP levels up to (~35%) compared to untreated OSW-1 washout 
cells (Figure 25B). Similar results were obtained with ALLN treatment in HeLa cells. The ALLn 










Figure 25: OSW-1 “washout effect” is not due to prolonged proteasomal degradation. 
(A)Continuous 1nM OSW-1 treatment in HCT-116 or HeLa with proteasome inhibitors (25 nM 
Bortezomib= BTZ, 25 nM Carfilzomib = CFZ, and 170 nM MG132) or calpain inhibitor (ALLN) 
results in significant protection of OSBP levels after 24 hours. (B) OSW-1 compound washout 
experiment (6-hour treatment, recovery time of 48 hours) with 1nM OSW-1 treatment results in 
long term repression of OSBP and addition of select proteasome inhibitors or ALLN at 24 hr pWo 
show partial recovery of OSBP. ALLN results collected by Mr. Ryan Bensen. (Full blots in Figure 





3.3.2 OSW-1 “washout effect” induces autophagy, but autophagy is not the cause of long-term 
OSBP repression. 
With proteasome degradation eliminated as the mechanism of long-term OSBP repression 
in OSW-1 washout cells, we then determined if the repression of OSBP could be due to autophagy 
proteolysis. The OSBP-binding natural product compound Schweinfurthin G (see 1.5.2 
Schweinfurthins) was shown to disrupt AKT signaling and to induce autophagy (135). We found 
that OSW-1 washout treatment induces autophagy in HEK293 cells by monitoring the known 
markers of induced autophagy: LC3A/B and p62 (Figure 26A & B) (see 1.6.5 Autophagy 
Induces and Inhibitors). Chloroquine (CQ) is a chemical inhibitor of the proteolysis of 
autophagic substrates, and therefore co-administration of CQ is required to measure LC3B levels 
during autophagy. Rapamycin (Rap) is a mTORC1 inhibitor that induces autophagy in cells. 
Similar to Rap/CQ treatment, OSW-1 compound/CQ treatment causes a noticeable increase in 
LC3B levels relative to CQ treatment alone in HEK-293 cells over the time course observed 
(Figure 26A, lower band), indicating the induction of autophagy (Figure 26A). Additionally, 1 
nM OSW-1 compound treatment for 6 hours resulted in ~60% reduction in p62 levels (Figure 
26B). The p62 levels returned to normal 24 hours post-washout, indicating that the autophagy 
triggered by the OSW-1 compound washout treatment is transient. (Figure 26A & B). Despite this 
transient autophagy that is induced, co-incubation with 25 µM CQ and 1 nM OSW-1 for 6 hours, 
followed by compound washout and replacement of 25 µM CQ for 24 hours does not result in 
OSBP rescue (Figure 26C). Confirming autophagy is not involved in OSBP reduction, cell 
splitting and cell dilution do not rescue OSBP levels despite increased nutrient availability that 
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would inhibit autophagy(219) (Figure 59). These results confirm that long-term OSBP reduction 
is not due to sustained autophagy or proteasome induced degradation. 
Figure 26: OSW-1 “washout effect” induces autophagy, but autophagy is not the cause of 
long-term OSBP repression. Treatment of HEK-293 cells for 6 hours with 1 nM OSW-1 
decreases (A) p62 and (B) increases LC3B (lower band on Western blot), which are markers of 
cellular autophagy. Rap= Rapamycin, a known autophagy inducing compound and CQ= 
chloroquine, a known autophagy inhibitor. (C) Inhibition of autophagy-induced proteolysis using 
25 µM CQ in HEK-293 cells does not rescue OSBP levels in OSW-1 washout experiment (i.e., 6-
hour, 1 nM OSW-1 treatment, followed by compound washout and 24-hour recovery). CQ 
treatment increases OSBP levels compared to DMSO vehicle control in cells. Work was completed 
by Mr. Zachary Severance. (Full blots in Figure 56, Figure 57 & Figure 58). The author had no 
contribution to the autophagy results. 
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3.3.3 Sustained OSBP loss is not due to rapid protein turnover 
We next determined if translational repression could be responsible for the compound-
triggered sustained reduction of OSBP levels. To identify if translational repression was occurring 
we determined the half-life of OSBP by using the translational inhibitor cycloheximide (CHX). 
CHX blocks the translocation step in protein synthesis, leading to inhibition of translational 
elongation. If OSW-1 treatment causes translational repression of OSBP, the protein half-life 
should overlap with the degradation of the protein under continual treatment with OSW-1 (Figure 
17B). HCT116 cells were treated with 178 µM CHX for the indicated time and OSBP protein 
levels were determined by Western blotting. The results show that the half-life of the control 
protein, p21, is ~2 hours which is consistent with previous reports(220–222) (Figure 27B). OSBP 
has a half-life of longer than 24 hours; at 24 hours, the CHX-induced protein translation block 
begins to be toxic to the cells. The half-life of OSBP was also determined in the HEK293 cell line 
and showed similar results (Figure 61A) Similarly, ORP4 half-life correlates with OSBP, in that 
it is over 24 hours in the HCT116 cell line (Figure 61B). This is the first reported protein turnover 
rate of OSBP and ORP4. The long lifespan of OSBP in cells indicates that the long-term, 
compound induced reduction of OSBP levels is not due to rapid cycling of the protein under normal 
conditions (Figure 27A). The rapid reduction of OSBP upon OSW-1 treatment is not a standard 
cellular process, but instead the compound treatment causes a different process of OSBP regulation 
to become activated.  
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Figure 27: Sustained OSBP loss is not due to rapid protein turnover. (A) OSBP half-life is 
over 24 hrs as determined by 178 µM cycloheximide while (B) p21 has a relatively short protein 
half-life and serves as a control. (Full blots in Figure 60). 
 
3.3.4 OSBP mRNA transcript remains stable throughout washout recovery. 
Since post-translational and translational repression are not responsible for the long-term 
repression of OSBP upon OSW-1 compound treatment, the effect of OSW-1 compound treatment 
on OSBP mRNA levels was determined. RT-PCR analysis using intron spanning primers of the 
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OSBP mRNA of OSW-1 compound washout treated cells show that OSBP mRNA levels were are 
not changed relative to the DMSO vehicle control from 0-72 hours post washout (Figure 28A). 
This result clearly shows that transcriptional repression of OSBP mRNA levels is not responsible 
for the long-term reduction of OSBP protein levels triggered by OSW-1 treatment. 
3.3.5 OSW-1 Compound Triggered Long-term Reduction of OSBP Levels is Specific for OSBP 
and Not a General Proteome Reduction 
Cellular iTRAQ proteomic analysis demonstrates that the OSW-1 compound washout 
treatment in HEK293 cells does not induce broad degradation of cellular proteins (Figure 28B & 
C). Only a few of the (469) proteins confidently identified and quantified in the iTRAQ experiment 
showed significant changes in measured level (p <0.05) at 24-hour post-washout, and the 
expression levels for these proteins return to levels similar to the vehicle control at 72-hour post-
washout. The top three most significantly changed proteins are: PEBP1 
(phosphatidylethanolamine-binding protein 1), a negative regulator of autophagy and RAF kinase 
inhibitor; RPL13 (60s Ribosomal Protein L13), a component of the large ribosome; and EIF4G1, 
a eukaryotic translation initiation scaffold protein. At the 24-hour recovery time point post-
washout, many of the quantified proteins exhibit a small non-significant (p>0.05) reduction in 
expression levels (Figure 28C & D), which might indicate a possible decrease in translation rate.  
The statistically significant (p <0.05) decrease in the proteins RPL13, EIF4G1, EEF1A2, DARS2, 
which are involved in multiple levels of protein translation, could contribute to the general, non-
significant reduction of many identified proteins 24 hours post-washout. The iTRAQ results, in 
combination with the lack of cytotoxicity and growth arrest in the OSW-1 compound washout 
experiment (Figure 21), indicate that the reduction of OSBP is targeted for that specific protein 
and is not the result of a widespread reduction of 
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Figure 28: OSW-1 compound washout does not induce OSBP transcript loss or 
wide-spread protein loss. (A) RT-PCR quantification of OSBP mRNA levels shows 
no reduction in transcript up to 72-hour pWO during the OSW-1 washout experiment 
(6-hour, 1 nM treatment) in HCT116 cells. (B) iTRAQ LC/MS/MS analysis (n=3) of 
OSW-1 compound treated lysates relative to vehicle control. All significantly changed 
proteins were decreased (24-hour pWO), except for SSBP1 (Single Stranded Binding 
Protein 1), which showed a slight increase in protein levels 72-hour pWO. (C) Table of 
proteins with significant changes (<0.05). Trend shows significant deviation from 
vehicle control protein levels after 24-hour pWO and begin to return to control levels 
72-hour pWO. iTRAQ analysis was conducted by Mr. Zachery Severance and analyzed 
by Dr. Si Wu’s lab. The author had no contribution to producing the iTRAQ results. 
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cellular proteins. Taken together, these results suggest a possible unique method of long-term 
protein reduction that cannot be fully explained by a single mechanism. 
3.4 Discussion 
The initial degradation of OSBP due to OSW-1 treatment is proteasome dependent as 
suggested by the protection afforded by the proteasome and calpain inhibitors (Figure 25A). 
While the initial loss of the protein is by the proteasome, the reduction seen during the post-
washout recovery cannot be fully explained by these mechanisms. Addition of proteasome and 
calpain inhibitors during the recovery phase after OSW-1 compound washout did not rescue 
OSBP levels completely, but did show some protective effects resulting in more accumulation of 
OSBP during recovery (Figure 25B). This suggests that either the proteasome is only partially 
responsible for the long-term OSBP reduction, or the OSW-1 induced cellular mechanism is 
disrupted by these compounds and triggers small amounts of expression. The calpain inhibitor 
ALLN protects OSBP to the same extent as the proteasome inhibitor bortezomib during 
continual treatment which is potentially due the promiscuity of the compound. ALLN can inhibit 
most major proteases and has a Ki of 6 µM for the proteasome(168). The treatment concentration 
of 10 µM could inhibit not only calpain activity but also that of the proteasome. This overlap of 
inhibition helps to reconfirm the idea that neither proteolysis method is responsible for the long-
term loss of OSBP. 
Cycloheximide chase experiments found that the half-life of OSBP is over 24 hours 
(Figure 27A), which is considered standard because most of the proteome has a half-life between 
20 and 40 hours(223). The initial loss of OSBP upon OSW-1 treatment (Figure 17B) appears to 
be an active process that occurs relatively quickly compared to the natural turn-over of the protein 
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(Figure 27A). Despite the quick degradation and prolonged loss of the protein, the mRNA of 
OSBP stays at a constant level throughout the recovery period (Figure 28A). 
Interestingly, thapsigargin treatment in INS-1E cells has a similar effect on GRP78 protein 
as OSW-1 washout treatment has on OSBP(224). Thapsigargin treatment usually causes an 
increase in GRP78, but in INS-1E cells GRP78 protein levels decrease(224). mRNA levels are 
increased throughout treatment time and proteasomal degradation of GRP78 is only partially 
responsible for reduction(224). Similarly, treatment of macrophages with the trichothecene 
mycotoxin deoxynivalenol also led to degradation of GRP78 protein but not mRNA levels, 
resulting in an ER stress response(225). Continual treatment of OSW-1 has also been shown to 
decrease GRP78 levels after 24 hours(130), suggesting a possible overlap of response to the 
compounds through an ER induced stress mechanism. More studies need to be conducted to 
determine if ER stress is induced during the washout treatment. 
Despite the possibility of ER stress induced reduction of OSBP, it is highly unlikely that 
the stress response could be sustained for multiple days without loss of viability. An alternative 
explanation for the reduction could be due to mRNA sequestration into p-bodies because of a stress 
event(226), which could be supported by the fact that the mRNA level of OSBP does not change 
throughout the recovery period. mRNA sequestration or a specific inhibition of OSBP mRNA 
translation through micro RNA (miRNA) are possible routes to explain the observed OSBP 
repression. ORP6(64), ORP8(227), and ORP9(228), close relatives of OSBP, are targeted by 
certain miRNAs to regulate homeostasis of cholesterol, insulin-mediated AKT activation, and lipid 
uptake respectively(64, 227, 228). Additionally, OSBP mRNA is reportedly targeted by a brain-
specific miRNA during neurite elongation(229). However, it is currently unclear how the OSW-1 
compound binding to and inducing the degradation of OSBP would then trigger a specific 
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suppression of subsequent OSBP levels, through miRNA targeting or any other mechanism. 
Additional experiments need to be performed to determine the exact mechanism of long-term 
OSBP reduction by OSW-1 treatment. 
3.5 Conclusion 
These results show the OSW-1 compound induced repression of OSBP proceeds through 
an unknown but non-typical cellular regulatory mechanism. This OSW-1 induced repression of 
OSBP is specific for OSBP and does not cause a global or wide spread change of protein levels. 
The OSW-1 compound induces a rapid loss of OSBP through proteasomal degradation, but the 
long-term repression of OSBP levels is not due to the proteasome. OSW-1 compound treatment is 
shown to induce autophagy for the first time, but the long-term reduction of OSBP levels triggered 
by the OSW-1 washout condition is not due to autophagy-induced proteolysis. The previously 
unknown half-lives of OSBP and ORP4 were established to be over 24 hours in cells. This shows 
that OSBP is not a short lived, rapidly-turned over protein, but has a longevity similar to the 
majority of cellular proteins(223). The rapid OSW-1 induced reduction of OSBP levels, and the 
long-term repression of OSBP caused by the compound in the washout condition clearly indicate 
a different cellular regulation of OSBP is being triggered. The OSBP mRNA transcript levels are 
not affected by OSW-1 compound treatment, including up to 48 and 72 hours post-washout. Future 
research is needed to identify the cellular mechanisms responsible for the long-term OSBP 
reduction triggered by OSW-1 compound treatment. A possible mechanism could be miRNA 
targeting of OSBP mRNA in OSW-1 compound treated cells.  
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3.6 Methods 
3.6.1 Cell Culture 
HEK293 STF (ATCC CRL-3249) and HeLa (ATCC CCL-2) were cultured in DMEM 
(Thermo 11995073) supplemented with 10% Hyclone (Fisher Sci SH3006603) and 1% penicillin-
streptomycin (Thermo 15140122). HCT116 (ATCC CCL-247) was cultured in McCoy 5A media 
(Thermo 16600108) supplemented with 10% Hyclone and 1% penicillin streptomycin. HCT116 
p21-/- cells were a gift from the Vogelstein Laboratory (Johns Hopkins University) and cultured 
in McCoy 5A media (Thermo 16600108) supplemented with 10% Hyclone and 1% penicillin 
streptomycin. 
3.6.2 General Cell Culture 
All mammalian cell lines were cultured at 37 ºC in 5% CO2. All handling of the 
mammalian cell culture was performed in a standard tissue culture hood using standard aseptic 
technique. Cell lines were cultured in the complete media described above. Cell culture stocks 
were aliquoted in complete media with 10% DMSO in 2 mL cryogenic vials (Corning 430659) 
and stored in liquid nitrogen vapor phase. Before beginning a new culture, the freezer stocks were 
thawed, diluted in 9 mL complete media and plated in Nunclon Delta 10 cm3 dishes (VWR 
10171744). After allowing ~16 hours for the revived cells to attach, the DMSO containing media 
was replaced with DMSO free complete media. All revived cultures were split at least twice prior 
to use in an experiment. Cell cultures were restarted approximately every 3-4 weeks. All cell-based 
experiments reported used multiple restarted cell cultures in the independent experiments that 
make up the replicate results. For experiments, cell cultures were used with a confluency of ~70%. 
The cell cultures were not allowed to ever become superconfluent, and the cellular morphology 
and proliferation rate of the cell culture was carefully tracked to identify any abnormalities; any 
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cell culture showing the slightest abnormalities were discard and the cell line restarted from frozen 
stocks. For experiments, cells were allowed to recover from splitting and replating a minimum of 
16 hr prior to the start of an experiment. 
The adherent mammalian cell lines are split every ~3 days with the following general 
procedure: the complete media is removed via aspiration and the cells are gently washed with 5 
mL of 1X PBS. TrypLE trypsin reagent (2.5 mL for 10 cm3 plate) is added and incubated for 
approximately 10 min at 37 ºC. After 10 mins 7.5 mL of the complete culture media is added to 
inactivate the TrypLE reagent. Cells were counted using a TC20™ Automated Cell Counter 
(BioRad), by combining 10 µL of cell solution with 10 µL Trypan Blue stain (Thermo 15250061). 
3.6.3 OSW-1 Compound 
The OSW-1 compound used was obtained through total synthesis in the Burgett lab or from 
isolation from the natural source. OSW-1 used in the experiments was of >95% purity as 
determined with 1H-NMR and LCMS analysis. Solid OSW-1 compound was dissolved in 
analytical grade DMSO solution to produce 10mM stocks for experimentation. The 10 mM OSW-
1 stock solution was aliquoted into Eppendorf brand 1.5 mL centrifuge tubes; Each individual 10 
mM OSW-1 aliquots were thawed no more than three times. Additional cycles of freeze/thaws 
caused partial loss of OSW-1 compound in the aliquots. 
3.6.4 Cell Lysis 
Cells were cultured in Nunclon Delta 10 cm3 dishes (VWR 10171744) and prepared for 
lysis by removing the media, washing with 1X PBS, followed by addition of 1 mL PBS and 
scraping. Cells were collected in a 1.5 mL Eppendorf brand centrifuge tubes and centrifuged at 
14,000 x g for 45 seconds. Supernatant was removed, and the cells were resuspended in 50 µL of 
AC Lysis buffer (150 mM NaCl, 1.5 mM MgCl2, 5% glycerol, 0.8% NP40, 1mM DTT, 50 mM 
88 
HEPES, 25 mM NaF, 1 mM Na3PO4) with 3X HALT/EDTA protease inhibitor (Thermo 78438) 
and 0.2 mM phenylmethanesulfonylfluoride (Goldbio). Cell lysis was performed by freezing cells 
in liquid nitrogen and thawing in a 37°C bead bath three times, followed by a 14,000 x g 
centrifugation for 15 minutes. Supernatant was transferred to a new tube and a portion was taken 
for protein quantification using a Bradford assay (Bio-Rad Protein Assay Dye Reagent 
Concentrate #5000006, BSA-Santa Cruz sc-2323). After protein quantification, the lysates were 
diluted to the desired concentration using AC lysis buffer and a final concentration of 1X Laemmli 
buffer (1 M Tris pH 6.8, 8% SDS, 40% glycerol, 20% β-mercaptoethanol, and 0.2% bromophenol 
blue), followed by dry bath heating at 95°C for 10 minutes. 
Cells cultured on 6-well plates (Greiner 657160) were prepared for lysis by removing 
media, washing with 1X PBS, followed by adding 0.5 mL TrypLETM Express (Gibco 12605010) 
and incubated at 37°C for 5 minutes. TrypLETM was neutralized using 0.5 mL of media and cells 
were then transferred to a 1.5 mL Eppendorf tube and centrifuged at 14,000 x g for 45 seconds. 
Supernatant was removed, and 1 mL of PBS was added to wash the cells. Cells were centrifuged 
at 14,000 x g for 45 seconds, supernatant was removed, and the cells were resuspended in 50 µL 
of AC lysis buffer. Freeze/thaw lysis method was continued as described above. 
3.6.5 Western Blotting 
SDS-PAGE gels (8.5 or 12%) containing 25 µg of total protein per well were transferred 
to 0.45 µm nitrocellulose (Bio-Rad 1620115) using constant voltage (100V) for 1 hour at 4°C in 
1X transfer buffer with 10% ethanol. After transferring, the nitrocellulose membrane was blocked 
with 5% milk 1X TBST at room temperature for 30 minutes. The membranes were then washed 
three times, five minutes each, with 1X TBST. Primary incubation with antibodies was done 
overnight at 4°C. After primary incubation, the blots were washed five times, five minutes each, 
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with 1X TBST and then incubated in secondary antibody in 1% milk TBST for thirty minutes at 
room temperature. After secondary antibody incubation, the blots were washed five times, five 
minutes each, with 1X TBST and then once with 1X TBS for ten minutes. TBS was removed, and 
the blots were incubated in ClarityTM Western ECL substrate (Bio-Rad 1705061) and imaged on 
the Bio-Rad ChemiDocTM Touch Imaging System using the chemiluminescence setting with 2x2 
binning. Ladder images were taken using the colorimetric setting. After development, the 
membranes were washed with 1X TBST twice for five minutes each. 1:1000 β-actin HRP (Santa 
Cruz sc-47778 HRP) in 1% milk TBST was added and incubated for 1.5 hours at room 
temperature. Developing occurred the same as after secondary antibody incubation. Primary 
antibodies used were 1:500 OSBP A-5 (Santa Cruz sc-365771), 1:500 p21 C-19 (Santa Cruz sc-
397), 1:1000 OSBP2 B-1 (Santa Cruz sc-365922), 1:100 SQSTM1 (p62) D-3 (Santa Cruz sc-
28359) and 1:1000 LC3A/B D3U4C XP® (Cell Signaling 12741). Secondary antibodies used were 
1:1000-1:3000 goat anti-mouse IgG1-HRP (Santa Cruz sc-2060), 1:3000 goat anti-rabbit IgG-HRP 
(Santa Cruz sc-2004) and 1:2000 goat antirabbit IgG-HRP (Cell Signaling 7074S). 
3.6.6 Cycloheximide Chase Experiments 
HCT116 and HEK293 cells were seeded at 1.6x105 cell per well into six well plates 
(Greiner 657160) and left to rest for 20 hours. Media containing 177 µM cycloheximide (Sigma 
C7698-1G) was added to the plates and the cells were incubated for the times indicated before the 
cells were lysed and analyzed by Western blotting. 
3.6.7 Proteasome Inhibitor Assays 
HCT116 cells were seeded out into plates and left to rest for 20 hours. For the co-incubation 
experiments, the cells were treated with DMSO (Sigma 472301), 1 nM OSW-1, 25 nM Bortezomib 
(Sigma 5043140001), 25 nM Carfilzomib (AdooQ Bioscience A11278), 170 nM MG-132 (Sigma 
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474787), or a combination of treatments for 24 hours. Cells were lysed and analyzed by western 
blotting. For the washout experiments, the cells were treated with media containing DMSO or 1 
nM OSW-1 for 6 hours, washed 3 times with 5 mL of media, and then allowed to recover for 24 
hours. After the 24-hour recovery, one set of treatments were lysed as a control to ensure OSPB 
loss while the other cells were treated with media containing 25 nM Bortezomib, 25 nM 
Carfilzomib, 170 nM MG-132, or DMSO for 24 hours. Cells were lysed and analyzed by western 
blot. 
3.6.8 Calpain Anaysis 
For the continual treatment, HeLa cells were seeded out in a 6 well plate. Upon 70% 
confluency, cells were treated with DMSO, DMSO and ALLN (10µM), OSW-1 (1nM), or OSW-
1 (1nM) and ALLN (10µM) for 24 hours. Cells were lysed and analyzed following the 6-well lysis 
method and the western blot protocol. Under the washout experimental conditions, cells were 
treated with DMSO or OSW-1 (1nM) for 6 hours. Cells were washed out according to the washout 
experimental method. After 24-hour recovery, one set of DMSO and one set of OSW-1 was lysed 
following the 6 well lysis method. At the same time (24 hours post-wash), ALLN (10µM) was 
added to one set of DMSO and one set of OSW-1. The cells continued to incubate until 48 hours 
post-wash, at which point they were lysed and analyzed using the western blot method. 
Experiments and analysis were performed by Mr. Ryan Bensen 
3.6.9 RT-PCR Analysis 
HCT116 and HEK293 cells were seeded at 0.85x105 cells/mL into 10 cm3 plates and left 
to rest for 20 hours. Cells were treated in the same manner as the washout with 1 nM Taxol, 1 nM 
OSW-1, and DMSO and left to recover for 0-72 hours. Once each time point was reached, media 
was removed from cell plates and 1 mL of TRIzol (Thermo 15596026) was added to the plates and 
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cells were scraped and collected in a 1.5 mL Eppendorf tube and incubated at room temperature 
for 5 minutes to ensure nucleoprotein complex dissociation. To each tube, 0.2 mL of chloroform 
was added and incubated for 2.5 minutes at room temperature. The samples were then spun down 
at 12,000 x g for 15 minutes at 4°C. After spinning the upper aqueous phase was transferred into 
a fresh 1.5 mL Eppendorf tube. 0.5 mL of 100% isopropanol was added and the tubes were mixed 
by inversion followed by a 10-minute incubation at room temperature. Samples were then spun 
down at 12,000 x g for 10 minutes at 4°C. Supernatant was discarded and 1 mL of 75% ethanol 
was added to the pellet to wash the RNA. The sample was vortexed briefly to dislodge pellet and 
then spun down at 7,500 x g for 5 minutes at 4°C. Supernatant was discarded and pellets were left 
to air dry for 5 minutes, after which 100 µL of MQ H2O were added to resuspend the RNA. 
Samples were then heated at 60°C for 10 minutes. RNA concentration was taken using a nano-
drop before being stored at -80°C. cDNA was made by using the Maxima First Strand cDNA 
Synthesis Kit (Thermo K1671). 4 µg of RNA was added to a PCR tube containing µ1 L of 
dsDNase, 1 µL of 10x dsDNase buffer, and MQ H2O to 10 µL. PCR tube was then incubated at 
37°C for 2 minutes, placed on ice, spun down briefly, and placed back on ice. 1 µL of 100 mM 
DTT was added to the tube and incubated at 55°C for 5 minutes, placed on ice, spun down briefly, 
and placed back on ice. 1 µL of 10 mM dNTPs, 1 µL random primers, and MQ H2O to 15 µL. 
Tubes were briefly mixed and incubated at 65°C for 5 minutes, put on ice, spun down, and put 
back on ice. 4 µL of 5X RT buffer and 1 µL of Maxima enzyme were added to the tube and then 
incubated at 25°C for 20 minutes, 50° for 30 minutes, followed by an inactivation at 85°C for 5 
minutes. cDNA was stored at -20°C. cDNA synthesis was confirmed by PCR with intron spanning 
β-Actin primers. Once verification was confirmed, RT-PCR was set up using Fast SYBR Green 
(Thermo 4385612) with intron spanning primers (OSBP, ORP4, and β-Actin). 10 µL of Fast SYBR 
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Green was mixed with 0.3 µL of 100 µmoles forward and reverse primer solution, 1 µL of cDNA, 
and MQ H2O to 20 µL. Each gene was done in triplicate for each time point. The plate was then 
run on a Roche LightCycler480 using SYBR green protocol. 
3.6.10 Autophagy Experiments 
HEK293 cells were seeded into 10 cm2 plates. Upon 70% confluency, cells were treated 
with DMSO as a vehicle control, 1 nM OSW-1, 25 µM chloroquine, or 100nM rapamycin, or a 
combination of treatments for 6 hours in 10 mL DMEM media for each 10cm3 plate. After 6 hours, 
the media containing the OSW-1 compound was washed out with three separate 5 mL drug free 
media washes (same as the washout experimental protocol). Cells were then treated with either 
drug free media, 100 nM rapamycin, 25 µM chloroquine, or a combination of treatments, and 
allowed to recover from OSW-1 compound treatment for 6, 15, or 24 hours. After the indicated 
post washout time point, the cells were lysed using AC lysis buffer according to the cell lysis 
protocol described previously. Lysates were analyzed via Western blot using OSBP, SQSTM1 
(p62), and LC3-A/B antibodies, with β-actin antibody used as a loading control for quantification 
(antibody information can be found in ‘Western blotting’ experimental methods). Experiments and 
analysis were performed by Mr. Zachary Severance 
3.6.11 iTRAQ Experiments 
HEK293 cells were seeded and treated according to the 0-72-hour recovery washout 
experimental procedure previously described (1nM OSW-1 or DMSO, 6-hour treatment). After 
the desired post washout time point, the cells were lysed according to the AC lysis protocol (lysis 
method 1) using modified AC lysis buffer. The modified AC lysis buffer contained no DTT and 
only 3X HALT (no EDTA or PMSF) for protease inhibitor. Free thiols can interfere with the 
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cysteine blocking step prior to iTRAQ tagging and protease inhibitors were kept to a minimum to 
avoid inhibiting trypsin during the digestion process. 
Effective treatment was confirmed via Western blot using OSBP antibody and β-Actin 
antibody as a loading control. A Multiplex Buffer Kit (Sciex 4381664) was used for the denaturing, 
reducing, and blocking steps. Trypsin with CaCl2 (Sciex 4352157) was used for digestion; and 
iTRAQ Reagent-8Plex Multiplex Kit (Sciex 4390812) was used for iTRAQ labeling. These kits 
were utilized according to the iTRAQ Reagents- 8plex Protocol. After tagging, the pH of the 
samples was lowered to approximately 3, using 1N Phosphoric Acid, and ran through a cation-
exchange cartridge system (Sciex cationexchange cartridge 4326747, cartridge holder 4326688, 
outlet connector 4326690, and needleport adapter 4326689) to remove any substances that could 
interfere with LC/MS/MS analysis. The protein eluate was quantified using a NanoDrop OneC 
(Thermo). Samples were normalized to a "mixed" sample that contained 5.5 µg of protein from 
each sample. Only shared proteins in all 3 biological replicates were used to test for changes in 
different conditions. P-values were generated using multiple t-tests in GraphPad Prism 7 (P<0.05 
for significantly changed proteins). Volcano plots were also generated in GraphPad Prism 7 to 
display P values against fold changes between the two treatment conditions. Cell treatments, lysate 
tagging, and protein quantification confirmation were performed by Mr. Zachary Sevarance and 
the LC/MS/MS experiments and analysis were performed by Ms. Hongyan Ma; Ms. Ma is a 
graduate student in the lab of Dr. Si Wu, Department of Chemistry and Biochemistry, Univ. of 
Oklahoma.  
3.6.12 LC-MS/MS analysis of labeled peptides 
Mixed peptide samples were analyzed using the LC-MS/MS following previously published 
protocol(203, 230). Peptide samples were desalted, dried in SpeedVac, and resuspended in buffer 
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A (0.1% formic acid in water). 1 µg of the digested sample was injected onto a custom-packed 
C18 RPLC column (75 µm i.d., 150 mm length, 2 µm C18 resin, Thermo) using a Waters (Milford, 
MA, USA) nano-Acquity UPLC system, which is online coupled with a LTQ Orbitrap Velos Pro 
mass spectrometer (Thermo) through a custom nano-ESI interface. For peptide separation, a 100-
min gradient was applied from 3% buffer A to 35% buffer B (0.1% formic acid in acetonitrile). 
Full MS spectra were acquired at a resolution of 60K (m/z range between 350 and 2000). The data-
dependent higher-energy collisional dissociation (HCD) based MS/MS spectra were acquired at a 
resolution of 15K with a normalized collisional energy of 33% using the ten most abundant parent 
ions. Peptides were identified using MSGF+ to search LC-MS/MS against the annotated Uniprot 
human protein database(231, 232). Peptide identifications were filtered with a MSGF cut-off score 
lower than the calculated FDR<1% at the unique peptide level against decoy database. The iTRAQ 
reporter ion intensities of each HCD scan were extracted and analyzed using in-house developed 
software. Experiments and analysis were performed by Ms. Hongyan Ma; Ms. Ma is a graduate 
student in the lab of Dr. Si Wu, Department of Chemistry and Biochemistry, Univ. of Oklahoma.  
3.6.13 Cell Splitting and Density Experiment 
HEK293 cells were cultured to ~70% confluency and then treated with either 1 nM OSW-
1 compound or DMSO for 6 hours, followed by washout. Cells were split following protocol 
outlined in General Cell Culture. Cells were plated with placing back all of the cells (1:1), placing 
back half the cells (1:2), or placing back only 20% of the cells (1:5). All cells were allowed to 
recover for 24 hours before lysis and analysis by Western botting. 
3.6.14 Statistical Analysis 
Results are expressed as mean ± s.d. and are n=3 unless otherwise stated. All statistical 
tests were performed using GraphPad Prism 7.0. Comparison between groups were made by 
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using a one-way ANOVA with a follow up Dunnett’s test. The p values are reported using 






















Chapter 4: The compound OSW-1 is a unique ORPphillin that has 
prophylactic anti-viral capabilities 
The following chapter is partially taken from a previous unpublished prepared manuscript. 
This was a collaborative work that consists of the following authors: Brett L. Roberts, Zachary C. 
Severance, Ryan C. Bensen, Anh T. Le, Cori A. Malinky, Evan M. Mettenbrink, William J. 
Reddig, Earl L. Blewett, Anthony W. G. Burgett. 
Mr. Zachary Severance conducted the radioactive binding assay in Figure 32 
 and the HeLa cell protein determination in Figure 33. 
Mr. Ryan Bensen conducted the radioactive binding assay in Figure 32.  
Dr. Earl Blewett conducted the anti-viral assays in Figure 33. 
4.1 Abstract 
The genus Enterovirus contains many important human pathogens (e.g. coxsackievirus, 
enteroviruses, human rhinovirus, polio virus) that cause a variety of diseases that currently lack 
approved therapy. Targeting host proteins that are hijacked for use in a conserved viral replication 
step in the early stages of infection enables broad-spectrum inhibition and provides fundamental 
knowledge about how these viruses hijack cells for replication. Currently the host protein OSBP 
is a desirable target due to its involvement in the formation of viral replication organelles where it 
supplies cholesterol to maintain efficient membrane lipid homeostasis required for viral genome 
replication. Compounds that target OSBP, which are called ORPphillins (OSW-1, Itraconazole, 
TTP-8307, and T-00127-HEV2), have been shown to have broad-spectrum anti-enteroviral 
activity. Here we show that of the ORPphillins tested, only OSW-1 can reduce OSBP protein levels 
with treatment. OSW-1 and T-00127-HEV2 show competitive binding to OSBP in a radioactive 
25-OHC binding assay. T-00127-HEV2, but not oxysterols, can rescue OSBP levels in the 
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presence of OSW-1. Similarly, T-00127-HEV2 induces a ~2-fold change in the relative GI50 in the 
presence of OSW-1. All the compounds tested have anti-viral activity with continual treatment, 
but only OSW-1 induces an anti-viral response 24 hours after the compounds have been removed. 
Therefore, OSW-1 presents itself as the best candidate for further development as a broad spectrum 
anti-viral due to its prophylactic ability.              
4.2 Introduction 
Picornaviridae is a family of positive-sense RNA viruses with little therapeutic treatment, 
which includes many viruses that impact human health, one of the most notable being the 
Enteroviruses (see section 1.4.1.2 Enteroviruses). Oxysterol-binding protein (OSBP), a member 
of a highly conserved eukaryotic protein family, is associated with viral replication through its 
function as a lipid transport protein between the ER and Golgi (see section 1.4.1 OSBP Function 
in Virus Replication). The natural product OSW-1, is a high affinity ligand of OSBP and has 
broad-spectrum anti-enteroviral activity through inhibiting OSBP cellular functions (see section 
1.5.1 OSW-1). Recent literature has identified other OSBP binding compounds that have anti-
enteroviral activity, presumably through OSBP inhibition, but the cellular effects of these 
compounds on OSBP protein levels remain unknown (see section 1.5 ORPphillins and 
OSBP/ORP4). We have previously shown that short low nanomolar doses of OSW-1 followed by 
removal of the compound from cells leads to reduction of OSBP up to 72 hours post compound 
removal. Cells treated with this OSW-1 washout were also resistant to enteroviral infections post 
compound removal. 
In this study, we investigated a panel of OSBP targeting small molecules anti-viral abilities 
collectively as well determining their ability to produce a prophylactic anti-viral after compound 
washout. We show that OSW-1 is the only compound to produce a reduction in OSBP levels in a 
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panel of cell lines. Interestingly, co-incubation of THEV2, and to a lesser extent ITZ, with OSW-
1 could rescue OSBP levels but TTP could not. Direct binding assays reveal that THEV2 has a 
similar Ki to OSW-1, while the other compounds were non-determinable. We provide evidence 
that continual treatment of all the compounds show anti-viral activity, but OSW-1 is the only 
compound to show anti-viral activity following pretreatment and removal of the compound. This 
provides evidence that OSW-1 has a unique effect on the cellular biology of OSBP, which makes 
it a promising compound for anti-viral pursuit. 
4.3 Results 
4.3.1 OSW-1, but no other ORPphillin, affects cell growth or OSBP protein expression 
We found that none of the compounds, besides OSW-1, showed significant growth 
inhibition on HCT116 cells at the highest concentrations tested (Figure 29A). Treatment with 
OSW-1 and taxol gave GI50s  near previously reported values(46) (Figure 29A). Due to the 
solubility issues of ITZ and TTP, coupled with the lack of cytotoxicity, all compounds besides 
OSW-1 were tested at the highest soluble concentration (10µM). HCT116 cells were treated 
continual with the compounds for 24 hours to determine if they reduced OSBP levels similar to 
OSW-1 continual treatment. Only OSW-1 reduced OSBP protein levels in HCT116 cells (Figure 
29B). Similar results were seen in HEK293 cells over the same time course and treatments (Figure 
64). 
4.3.2 ORPphillins show differential localization patterns of OSBP 
To determine if the compounds affect OSBP cellular localization we utilized 
immunofluorescence microscopy in HCT116 cells. It is known that OSBP localizes to the trans-
Golgi network upon the addition of various ligands(11, 46, 81, 156). The imagining experiments 
used the OSBP antibody and an antibody recognizing the trans Golgi marker TGN46, as well as a 
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nuclear stain. Treatment with 25-OHC caused a clustered localization of OSBP with the trans-
Golgi marker TGN46 in HCT116 cells as previously reported(11, 46)(Figure 30). OSW-1 treated 
cells show a highly reduced signal, consistent with Western blotting, and show the remaining 
OSBP in a vesicle formation that is not associated with the TGN46 marker (Figure 30). The 
TGN46 signal in OSW-1 treated cells is also reduced and scattered, suggesting disruption of the 
Golgi-network due to loss of OSBP function. A phospho-memetic version of OSBP that is inactive 
was shown to have impaired Golgi localization which induced Golgi fragmentation(73). ITZ 
treatment shows a broader Golgi stain compared to DMSO but a vastly different OSBP staining 
(Figure 30). OSBP staining is very patchy but still mainly overlaps with the Golgi marker. TTP 
shows a very similar staining pattern to DMSO, but with intensified OSBP signal, which suggests 
that treatment causes more localization of OSBP to the Golgi in its native state (Figure 30). 
THEV2 is similar to 25-OHC staining, showing clustered OSBP and TGN46 signals (Figure 30). 
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Figure 29: OSW-1, but no other ORPphillin, affects cell growth or OSBP protein expression. 
(A) Effect on 48-hour growth of OSW-1, Taxol, ITZ, TTP, or THEV2 in HCT116 cells. (B) OSBP 
levels are reduced with OSW-1 (1 nM) but not the other compounds (10 µM) after 24 hours of 





Figure 30: ORPphillins show differential localization patterns of OSBP. OSBP (green) and 
TGN46 (red) were visualized in HCT116 cells using indirect immunofluorescence. Cells were 
treated with DMSO, 1 nM OSW-1, or 10 µM of 25-OHC, ITZ, TTP, or THEV2 for 24 hours. 
Nuclei (blue) were stained with Hoescht 33342. 
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4.3.3 Co-incubation with THEV2 or ITZ, but not oxysterols, can rescue OSBP loss induced by 
OSW-1 
We tested the compounds in tandem with OSW-1 to determine if any could rescue OSBP 
protein levels. It was previously reported that co-incubation of other OSBP ligands with OSW-1 
could rescue the expression level of OSBP(46). We found that THEV2 and ITZ significantly 
rescued OSBP levels to around 70% and 40% respectively in HCT116 cells (Figure 31A). 
Interestingly, TTP co-incubation was not different than OSW-1 alone, suggesting it could not out 
compete OSW-1 (Figure 31A). Similar results were obtained in HEK293 cells. 
Comparing the structures of the compounds (Figure 9, Figure 12 & Figure 13), THEV2 
is the most steroidal in structure and has the ability to localize OSBP similar to 25-OHC (Figure 
30). It was previously reported that 25-OHC treatment could rescue OSBP levels when 
administered with OSW-1(46). We tested if OSW-1 treatment along with 25-OHC or 20-α-OHC, 
two naturally occurring oxysterols, could rescue OSBP levels in HCT116 cells. Interestingly, we 





Figure 31: Co-incubation with THEV2 and ITZ, but not oxysterols, can rescue OSBP loss 
induced by OSW-1. HCT116 cells were treated with 1 nM OSW-1, DMSO, or a combination of 
10 µM ITZ (A), TTP (A), THEV2 (A), 25-OHC (B), or 20-α-OHC in combination with 1 nM 
OSW-1 for 24 hours and then analyzed by western blot. (Full blots in Figure 65) 
 
4.3.4 THEV2 binds OSBP competitively and suppresses OSW-1 cytotoxic activity. 
Based on the mixed results of localization and co-incubation rescue data, we determined 
the ability of each compound to competitively bind to OSBP. Using a previously established in 
vitro competitive binding assay with [3H]-25-OHC(46), we found that THEV2 binds 
competitively with OSBP while ITZ and TTP did not (Figure 32A & C). THEV2 and 25-OHC 
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have comparable binding affinity to OSBP and show similar localization patterns, yet THEV2 has 
the ability to rescue OSBP during OSW-1 co-incubation while 25-OHC does not (Figure 31, 
Figure 32A & C). Interestingly, ITZ does not bind OSBP competitively but was shown to have 
some protective ability in the co-incubation experiments (Figure 31A & Figure 32A). The unusual 
localization induced by ITZ (Figure 30) could be a result of the lack of competitive binding 
(Figure 32A). Not surprisingly, TTP does not display competitive binding to OSBP (Figure 32A), 
which was expected due to the lack of protection against OSW-1 induced OSBP protein reduction 
(Figure 31A). 
Our results from the co-incubation Western blot and cellular localization show mixed 
results for the compounds in terms of their competitive binding ability. Since the in vitro binding 
assay can only detect competitive binding, there is a possibility that ITZ and TTP can bind OSBP 
at a different site than OSW-1. To determine the effect of these compounds on OSBP in vivo, we 
conducted a 48-hour growth inhibition assay with co-incubations of OSW-1 and a set 
concentration of ITZ, TTP, or THEV in HeLa cells (Figure 32B &C). THEV2 co-incubation was 
able to significantly reduce OSW-1 growth inhibition by ~2 fold while ITZ and TTP co-incubation 
had little effect (Figure 32B & C). We also found that co-incubation with 1 nM OSW-1 and 10 
µM of the compounds showed similar viability changes as the growth inhibition assay after 24 
hours (Figure 66). 
Immunofluorescence microscopy in HCT116 cells revealed that the localization of OSBP 
with co-incubation of the compounds has similar results as the in vivo binding and growth 
inhibition assays (Figure 67). Co-incubation with THEV2 and OSW-1 shows a split pattern of 
slightly reduced OSBP staining clustered to Golgi staining similar to THEV2 alone (Figure 30 & 
Figure 67). There is also OSBP vesicle staining that is dissociated from the Golgi (Figure 30 & 
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Figure 67). Co-incubation of ITZ and OSW-1 showed a more clustered OSBP staining to the Golgi 
than ITZ by itself (Figure 30), but more OSBP signal was in vesicles dissociated from the Golgi 
(Figure 30 & Figure 67). TTP co-incubation resembles OSW-1 alone (Figure 30) with highly 
reduced OSBP signal in vesicles dissociated from the Golgi (Figure 67). These results suggest 








Figure 32: THEV2 binds OSBP competitively and suppresses OSW-1 cytotoxic activity. (A) 
THEV2 has a similar Ki values (C) as OSW-1 and 25-OHC while ITZ and TTP did not show 
competitive binding. (B) THEV shows significant protection against OSW-1 growth arrest (C) as 
determined by 48-hour co-incubation cell growth assay with OSW-1 and 10 µM of ORPphillins 
in HeLa cells. ITZ and TTP do not have any effect on cell growth when co-incubated with OSW-
1. (C) Table showing the Ki generated from (A), the relative GI50 as compared to OSW-1 and p 
value from a two-tailed t-test from (B). Nd= not determined and Na= not applicable. Data collected 
by Mr. Zachary Severance and Mr. Ryan Bensen. The author had no contribution to the results of 




4.3.5 OSW-1 exerts anti-viral activity 24 hours after compound has been removed 
We tested the ability of the ORPphillins to exert anti-viral activity against two clinically 
isolated Enteroviruses in Hela cells. The ORPphillins tested so far have been shown to exert anti-
viral activity on various enteroviruses through disruption of OSBP function(81, 82, 155, 156). All 
of the compounds inhibited viral replication of the two clinically isolated Enteroviruses under 
continual treatment, but treatment with OSW-1 was the most effective (Figure 33A). We have 
previously shown that OSW-1 is able to induce the degradation of OSBP during straight treatment 
(Figure 29B), but it can also reduce the OSBP protein levels for multiple days after a short non-
toxic treatment followed by removal of the compound we have termed washout experiments ( 
Figure 18). We conducted washout experiments with the compounds to determine if a 
similar anti-viral response to OSW-1 washout treatment could be induced (Figure 24B). In short, 
the cells were treated with compounds for six hours, followed by three rounds of washing with 
media and allowed to recover for 24 hours before being infected. We found that only OSW-1 could 
reduce OSBP protein levels in Hela cells under these conditions (Figure 33C) and was the only 




Figure 33:OSW-1 exerts anti-viral activity 24 hours after compound has been removed. (A) 
Viral titers of infected HeLa cells incubated in the presence of the compounds. Cells were treated 
with the indicated concentrations of compounds for 6 hours, followed by viral infection for 30 min 
(MOI of 1.0), followed by re-incubation for 10 hours with compounds (B) Viral titers in compound 
washout HeLa cells. Cells were treated with the indicated concentrations of compounds for 6 
hours, compounds were removed, cells were allowed to recover for 24 hours in compound-free 
media. Then, cells were infected for 30 min with virus (M.O.I.=1.0) followed by 10-hour 
incubation in compound-free media. (C) OSBP protein levels of compound washout HeLa cells at 
the 24-hour recovery point before infection. All viral assays were done by Dr. Earl Blewett and 
OSBP determination was done by Mr. Zachary Severance. (Full blot in Figure 68). The author 
had no contribution to producing these results 
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4.4 Discussion 
The biological effect of various anti-viral compounds targeting OSBP was assessed and of 
the compounds tested, only OSW-1 showed any cytotoxicity and could cause a reduction of OSBP 
levels at 1 nM of treatment. Treatment with the other compounds at 10 µM did not affect the 
protein level, which is not surprising since there was no cytotoxicity of the compounds in this 
range. These results reconfirm the idea that select OSBP ligands cause OSBP protein loss(46). 
The co-incubation of the compounds with OSW-1 treatment showed that ITZ and THEV2 
possess protective activity, but to different degrees. Although ITZ shows a modest protection of 
around 40%, the viability of cells treated with ITZ or ITZ+OSW-1 is similar to OSW-1 by itself 
(Figure 66). One of the possible reasons for the loss of viability during treatment with ITZ is due 
to its anti-cancer activity(148, 150, 233). THEV2 protects OSBP to around 70% and the viability 
with THEV2+OSW-1 is near that of untreated cells (Figure 66). This would suggest that THEV2 
can out compete OSW-1 interactions with OSBP without the loss of viability due to other cellular 
interactions. The in vitro competitive binding assay confirms this binding interaction, showing that 
of the compounds tested, THEV2 is similar to 25-OHC in its Ki and OSBP localization pattern 
(Figure 30 & Figure 32A). THEV2 is able to significantly increase the GI50 of OSW-1, suggesting 
the necessity to remove OSW-1 from the binding pocket to protect OSBP  
Interestingly, 25-OHC did not protect OSBP in a similar manner as previously reported(46) 
(Figure 31B). A possible explanation for this discrepancy is the loss of potency of OSW-1 stocks 
after multiple freeze/thaw cycles that we witnessed in previous experiments. It is quite possible 
that the stock compound used in the original experiments was diluted due to the hydroscopic nature 
of the DMSO solvent during the freeze/thaw cycles. We have shown previously that OSBP loss 
due to OSW-1 treatment is both time and concentration dependent (Figure 22B & Figure 46), so 
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this could explain how 25-OHC treatment would be able to protect OSBP during OSW-1 
treatments in the original experiments. For our experiments, we minimized the freeze/thaw cycle 
of aliquots to three times before discarding the aliquot for a new one. This experiment suggests 
that the protective effect of THEV2 is not solely due to the steroidal nature of the compound. 
Despite similar Ki values and localization patterns, there is a difference in the ability of THEV2 
and 25-OHC to rescue OSBP levels. This might be due to the availability of the compounds within 
the cells because 25-OHC is a promiscuous ligand interacting with various proteins(234). Further 
testing of THEV2 needs to be performed to understand its full effect within the cell. 
Although ITZ and TTP have no competitive binding, they demonstrate the ability to change 
the localization of OSBP, which suggests an alternative binding site. Previous studies have shown 
that ITZ binds to OSBP with a Kd of around 430 nM and that all eight stereoisomers of ITZ are 
able to induce OSBP re-localization and anti-viral activity (81, 235). This indicates a lose fitting 
interaction with OSBP(81, 235). This weak, non-competitive binding interaction could explain the 
slight rescue of OSBP witnessed during the co-incubation experiments. A previous study has 
shown that TTP inhibits the cholesterol and lipid transporting abilities of OSBP, but to a far lesser 
extent than ITZ(156). Based on the lack of competitive binding results, it might suggest that TTP 
binds to OSBP in a manner that allows for sterol binding but not transfer. TTP specific targeting 
of OSBP is questionable since overexpression of OSBP was not able to rescue viral replication, 
suggesting interaction with other targets that are involved in viral replication(156). It seems that 
both molecules have weak affinity for OSBP, but may interact with multiple targets within cells, 
calling their use as antivirals into question. 
Unsurprisingly, all the compounds exhibited anti-viral activity when tested under 
continuous treatment conditions (Figure 33A). The log-fold inhibition of viral titers is highest 
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with OSW-1, despite being 1,000-fold less concentrated than the other compounds. This suggests 
OSW-1 is more specific for OSBP than THEV2, since the compounds have similar Ki values 
(Figure 32C & Figure 33A). Despite the differences in log-fold inhibition, all the compounds can 
inhibit replication to at least 20% compared to the control, suggesting a strong anti-viral response 
(Figure 33A). OSW-1 was the only compound to induce an anti-viral response 24-hours after the 
compound was removed from cells (Figure 33B). This anti-viral activity is presumably due to the 
ability of OSW-1 washout treatment to induce long-term reduction of OSBP (Figure 33C). This 
result is significant because initial treatment with OSW-1 was in the low nanomolar range for only 
a few hours before removal and the anti-viral effect persists for over 40 hours after the compound 
was first introduced to cells. This provides more evidence that OSW-1 is a specific inhibitor of 
OSBP with strong capabilities for prophylactic anti-viral treatment. 
4.5 Conclusion 
Taken together, these findings highlight the uniqueness of OSW-1 in the pool of OSBP 
targeting anti-viral compounds. ITZ and TTP do not seem to be ideal candidates for anti-viral 
treatment due to their lack of high specificity for OSBP and the increased dose needed to produce 
the anti-viral response. Our research has increased the anti-viral knowledge of the THEV2 
compound by expanding the number of enteroviruses the compound has been tested against. 
THEV2 seems to be a unique compound, given its relatively low Ki for OSBP and ability to rescue 
OSBP expression in the company of OSW-1. Despite these characteristics, OSW-1 displays a 
stronger anti-viral replication response in the continual treatments with far less concentration. One 
of the potential reasons to deviate from using OSW-1 is the relatively high toxicity of the 
compound (~1 nM after 48 hours of continual treatment). We have shown that there is a way 
around this toxicity by removing the compound with the washout experiments and still retaining 
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the anti-viral response, which all the other anti-viral OSBP targeting compounds lack. These 
findings lead to potential of producing a prophylactic anti-viral treatment for a group of viruses 
which lack any current approved treatment options. Future research should focus on producing 
OSW-1 derivatives that preferentially target OSBP over ORP4 to fully optimize the potential of 
this finding. 
4.6 Methods 
4.6.1 Plasmids and Cloning 
Human OSBP cDNA was obtained in a pOTB7 vector from the Mammalian Gene 
Collection (Thermo). PCR using 5’-GCTAGCATGGCGGCGACGGAG-3’ forward and 
5’AAGCTTGAAAATGTCCGGGCATGAGC-3’ reverse primers amplified a 2.44 kb Nhe 
IHindIII fragment containing a full-length hOSBP cDNA, which was subcloned into pJET1.1 
(Thermo) and sequence verified. The fragment was then cloned into the pcDNA™ 3.1/myc-His(-
) C mammalian expression vector (Sigma) Nhe I-Hind III doublecut sites. The reverse primer does 
not include an additional nucleotide between HindIII cut site and the last OSBP codon resulting in 
an OSBP-tagless protein. ORP4L was cloned from HCT-116 with cDNA with a NheI forward 
primer 5’-GCTAGCATGGGGAAAGCG-3’ and a HindIII reverse  primer  5’-
AAGCTTCGAAGATGTTGGGGCACATATG-3'. LacZ was PCR amplified from K-12 E. coli 
with NotI forward 5’- GCGGCCGCATGCCCG TCGTTTTA-3’ and BamHI reverse primer 5’-
GGGCGGATCCTTTTTGAC ACCAGACCAA-3’. To generate the proteins expressing tags, the 
MCS of the completed vector was changed through site-directed mutagenesis with a forward 5’-
AAGCTTACGTACGAACAAAAACTCATCTCAGAAGAG3’ and reverse 5’-
CTCTTCTGAGATGAGTTTTTGTTCGTACGTAAGCTT-3’. The plasmid was expanded in E. 
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Coli DH5α, and isolated through miniprep and maxiprep kits (Thermo).  Gene and plasmid MCS 
were sequence verified through Oklahoma Medical Research Foundation (OMRF). 
4.6.2 Cell Lines and Viruses 
HEK293 STF (ATCC CRL-3249) and HeLa (ATCC CCL-2) were cultured in DMEM 
(Thermo 11995073) supplemented with 10% Hyclone (Fisher Sci SH3006603) and 1% penicillin-
streptomycin (Thermo 15140122). HCT116 (ATCC CCL-247) was cultured in McCoy 5A media 
(Thermo 16600108) supplemented with 10% Hyclone and 1% penicillin streptomycin. RD, 
(rhabdomyosarcoma) cells (ATCC-CCL-136) were cultured in DMEM (Fisher Sci SH30081.0) 
with 10% FBS (Atlanta Biological S11550) and 1% penicillin-streptomycin (Gibco 15140-122). 
Coxsackievirus A9 (strain CoxA9-01) and Echovirus 2 (strain Echo201) were obtained from the 
Oklahoma State Department of Health Laboratory. They are clinical isolates, obtained from OK 
residents and typed by the OK State Department of Health and/or the Center for Disease Control 
and Prevention. All other identifiers have been stripped off. These viruses were passaged twice in 
RD cells, aliquoted in 1.0 mL amounts and stored in complete medium at -80 ⁰C.  Each virus was 
titered on RD cells using a TCID-50 assay(210). To allow M.O.I . to be determined a 
conversion factor of 0.7 was used to change TCID-50 to pfu/ml. 
4.6.3 General Cell Culture 
All mammalian cell lines were cultured at 37 ºC in 5% CO2. All handling of the mammalian 
cell culture was performed in a standard tissue culture hood using standard aseptic technique. Cell 
lines were cultured in the complete media described above. Cell culture stocks were aliquoted in 
complete media with 10% DMSO in 2 mL cryogenic vials (Corning 430659) and stored in liquid 
nitrogen vapor phase. Before beginning a new culture, the freezer stocks were thawed, diluted in 
9 mL complete media and plated in Nunclon Delta 10 cm3 dishes (VWR 10171744). After allowing 
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~16 hours for the revived cells to attach, the DMSO containing media was replaced with DMSO 
free complete media. All revived cultures were split at least twice prior to use in an experiment. 
Cell cultures were restarted approximately every 3-4 weeks. All cell based experiments reported 
used multiple restarted cell cultures in the independent experiments that make up the replicate 
results. For experiments, cell cultures were used with a confluency of ~70%. The cell cultures were 
not allowed to ever become superconfluent, and the cellular morphology and proliferation rate of 
the cell culture was carefully tracked to identify any abnormalities; any cell culture showing the 
slightest abnormalities were discard and the cell line restarted from frozen stocks. For experiments, 
cells were allowed to recover from splitting and replating a minimum of 16 hour prior to the start 
of an experiment. 
Cell lines are split every ~3 days with the following general procedure: the complete media 
is removed via aspiration and the cells are gently washed with 5 mL of 1X PBS. TrypLE trypsin 
reagent (2.5 mL for 10 cm3 plate) is added and incubated for approximately 10 minutes at 37 ºC. 
After 10 minutes, 7.5 mL of the complete culture media is added to inactivate the TrypLE reagent. 
Cells were counted using a TC20™ Automated Cell Counter (BioRad), by combining 10 µL of 
cell solution with 10 µL Trypan Blue stain (Thermo 15250061). 
4.6.4 Compounds 
The OSW-1 compound used was obtained through total synthesis in the Burgett lab or from 
isolation from the natural source. OSW-1 used in the experiments was of >95% purity as 
determined with 1H-NMR and LCMS analysis. Solid OSW-1 compound was dissolved in 
analytical grade DMSO solution to produce 10mM stocks for experimentation. The 10 mM OSW-
1 stock solution was aliquoted into Eppendorf brand 1.5 mL centrifuge tubes; Each individual 10 
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mM OSW-1 aliquots were thawed no more than three times. Additional cycles of freeze/thaws 
caused partial loss of OSW-1 compound in the aliquots. 
4.6.5 Cell Lysis 
Cells were cultured in Nunclon Delta 10 cm3 dishes (VWR 10171744) and prepared for 
lysis by removing the media, washing with 1X PBS, followed by addition of 1 mL PBS and 
scraping. Cells were collected in a 1.5 mL Eppendorf brand centrifuge tubes and centrifuged at 
14,000 x g for 45 seconds. Supernatant was removed, and the cells were resuspended in 50 µL of 
AC Lysis buffer (150 mM NaCl, 1.5 mM MgCl2, 5% glycerol, 0.8% NP40, 1mM DTT, 50 mM 
HEPES, 25 mM NaF, 1 mM Na3PO4) with 3X HALT/EDTA protease inhibitor (Thermo 78438) 
and 0.2 mM phenylmethanesulfonylfluoride (Goldbio). Cells were lysed by freezing in liquid 
nitrogen and thawing in a 37°C bead bath three times, followed by a 14,000 x g centrifugation for 
15 minutes. Supernatant was transferred to a new tube and a portion was taken for protein 
quantification using a Bradford assay (Bio-Rad Protein Assay Dye Reagent Concentrate 
#5000006, BSA-Santa Cruz sc-2323). After protein quantification, the lysates were diluted to the 
desired concentration using AC lysis buffer and a final concentration of 1X Laemmli buffer (1 M 
Tris pH 6.8, 8% SDS, 40% glycerol, 20% β-mercaptoethanol, and 0.2% bromophenol blue), 
followed by dry bath heating at 95°C for 10 minutes. 
Cells cultured on 6-well plates (Greiner 657160) were prepared for lysis by removing 
media, washing with 1X PBS, followed by adding 0.5 mL TrypLETM Express (Gibco 12605010) 
and incubated at 37°C for 5 minutes. TrypLETM was neutralized using 0.5 mL of media and cells 
were then transferred to a 1.5 mL Eppendorf tube and centrifuged at 14,000 x g for 45 seconds. 
Supernatant was removed, and 1 mL of PBS was added to wash the cells. Cells were centrifuged 
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at 14,000 x g for 45 seconds, supernatant was removed, and the cells were resuspended in 50 µL 
of AC lysis buffer. Freeze/thaw lysis method was continued as described above. 
4.6.6 Western Blotting 
SDS-PAGE gels (8.5%) containing 25 µg of total protein per well were transferred to 0.45 
µm nitrocellulose (Bio-Rad 1620115) using constant voltage (100V) for 1 hour at 4°C in 1X 
transfer buffer with 10% ethanol. After transferring, the nitrocellulose membrane was blocked with 
5% milk 1X TBST at room temperature for 30 minutes. The membranes were then washed three 
times, five minutes each, with 1X TBST. Primary incubation with antibodies was done overnight 
at 4°C. After primary incubation, the blots were washed five times, five minutes each, with 1X 
TBST and then incubated in secondary antibody in 1% milk TBST for thirty minutes at room 
temperature. After secondary antibody incubation, the blots were washed five times, five minutes 
each, with 1X TBST and then once with 1X TBS for ten minutes. TBS was removed, and the blots 
were incubated in ClarityTM Western ECL substrate (Bio-Rad 1705061) and imaged on the Bio-
Rad ChemiDocTM Touch Imaging System using the chemiluminescence setting with 2x2 binning. 
Ladder images were taken using the colorimetric setting. After development, the membranes were 
washed with 1X TBST twice for five minutes each. 1:1000 β-actin HRP (Santa Cruz sc-47778 
HRP) in 1% milk TBST was added and incubated for 1.5 hours at room temperature. Developing 
occurred the same as after secondary antibody incubation. Primary antibody used was 1:500 OSBP 
A-5 (Santa Cruz sc-365771). Secondary antibody used was 1:1000-1:3000 goat anti-mouse IgG1-
HRP (Santa Cruz sc-2060). 
4.6.7 ORPphillin Compound Treatments and Cell Viability Assay 
HCT116 and HEK293 cells were seeded out 5x105 into 6 well plates and left to rest for 20 
hours. For the co-incubation experiments the cells were treated with DMSO (Sigma 472301), 1 
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nM OSW-1, 1 nM Taxol, 10µM Itraconazole (Sigma I6657), 10µM TTP, 10µM T-00127-HEV2, 
or a combination of treatments for 24 hours. Cells were washed with 1X PBS and then incubated 
in 0.5 mL TrypLETM for five minutes at 37°C. Reaction was neutralized using 0.5 mL of fresh 
media and cells were counted on a TC20™ Automated Cell Counter (BioRad) by combining 10 
µL of cell solution with 10 µL Trypan Blue stain (Thermo 15250061). The rest of the cell solution 
was lysed and analyzed by western blotting. 
4.6.8 Sterol Treatments 
HCT116 cells were seeded out 5x105 into 6 well plates and left to rest for 20 hours. For the 
co-incubation experiments the cells were treated with 100% Ethanol, 1 nM OSW-1, 10 µM 25-
hydroxycholsterol (Cayman Chemical 11097), 10 µM 20-α-hydroxycholesterol (Cayman 
Chemical 20103), or a mixture for 24 hours. Cells were lysed and analyzed by western blotting. 
4.6.9 Immunofluorescence 
HCT116 cells were seeded at 50,000 cells onto sterile 18 mm cover slips in 12 well plates 
for treatments lasting 24 hrs. The cells rested for 24 hours before treatment to ensure attachment 
of the cells. Once treatments were completed, media was removed and cells were washed with 
warm 1X PBS. PBS was removed and 0.5 mL of freshly prepared 4% paraformaldehyde in PBS 
was added. Cover slips were at 37°C for 20 minutes and then the paraformaldehyde was removed 
followed by three 1X PBS washes. Permeabilization of the cells was done with 0.5 mL of 0.5% 
Triton X-100 in PBS at room temperature for 10 minutes. 1X PBS was used to wash the cells three 
times. Image-iT FX signal enhancer (Thermo I36933) was added onto the cover slips, and incubate 
at room temperature for 30 minutes followed by three 1X PBS washes. Coverslips were blocked 
with 0.5 mL of 1% BSA in PBS at room temperature for 30 minutes followed by three washes 
with 1X PBS. Primary antibody was added and the slips were incubated overnight at 4°C. The 
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primary antibody solution was removed and the cover slips were washed three times with 1X PBS. 
Secondary antibody was incubated in darkness at room temperature for one hour. Removed the 
secondary antibody solution and washed three times with 1% BSA-PBS, three times with 1X PBS, 
and then soaked the cover slip in 300 nM DAPI (Thermo D1306) solution for 10 minutes Mounted 
the slips onto glass slides using VECTASHEILD HardSet Antifade mounting media (VECTOR 
labs H-1400). Stored slides at -20°C until imaging was conducted. Primary antibodies used were 
1:100 OSBP1 1F2 (Novus NBP2-00935) and 1:500 TGN46 (Novus NBP1-49643). Secondary 
antibodies used were 1:500 goat anti-mouse IgG H&L Alexa Fluor® 488 (Abcam ab150113) and 
donkey anti-rabbit IgG H&L Alexa Fluor® 594 (Abcam ab150076). Imaging was done with a 
Lecia SP8 using a 63x objective with 2x digital zoom. Images were analyzed with ImageJ software. 
4.6.10 Cytotoxicity Assay 
HCT116 cells were seeded out at 2,000 cells per well into opaque 96 well Falcon plates 
(VWR 25382-208). Cells were allowed to rest for 20 hours before treatments. Day zero control 
plate was created by adding 25 µL of media containing either 0.1% DMSO or 1% DMSO and 20 
µL of cell titer blue (Promega G8081) to each of the wells containing cells. Incubated at 37°C with 
5% CO2 for 1 hour and 30 minutes. Plates were read using a GloMax® Discover using the Cell 
Titer Blue protocol. Remaining plates with cells were treated with various dilutions of drugs and 
incubated at 37°C for 48 hours under 5% CO2. After the incubation time, 20 µL of cell titer blue 
was added to the wells and the plates were incubated and read as incubated above. Control plate 
was subtracted from the treatment plate and the values were analyzed using GraphPad Prism 
software. 
Co-incubation experiments were done using the same protocol above by Mr. Zachary 
Severance with HeLa cells seeded out at 5,000 cells per well. 10µM of ITZ, TTP, or THEV2 were 
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added to all the wells during the 48-hour treatment and the OSW-1 concentration was varied 
between wells. 
4.6.11 ([3H]-25-OHC) Charcoal/Dextran Binding Assay 
The [3H]-25-OHC binding assay was run according to the protocol outlined in Burgett et 
al(46) by Mr. Zachary Severance and Mr. Ryan Bensen. 
4.6.12 Antiviral Experiments 
HeLa cells were grown to <75% confluency (healthy log phase cells) in complete media, 
DMEM (Hyclone SH30081.0) with 10% FBS (Atlanta Biological S11550) and 1% penicillin-
streptomycin (Gibco 15140-122). For experiments, cells were trypsinized, counted using a 
hemocytometer and seeded into 20 wells of two 24-well trays (Falcon 3047) with 2.0 x 105 cells 
per well, in 1.0 mL complete media. Each treatment is performed using quadruplicate wells (n=4) 
and each virus was on a separate plate. After seeding, cells were incubated 20 hour at 37 ºC, 5% 
CO2, at which point cells have grown to a near confluent monolayer. 
For the continual compound treatment experiments, (Figure 33A), the media was gently 
removed from each well, and 1mL of media was added with the desired compound concentration 
to each well, without disturbing the cells. Cells were incubated for 6 hours, after which time the 
media was removed and cells were gently washed three times with 1.0 mL of FBS-free DMEM 
media. After the media was removed, CoxA9-01 or Echo2-01 viruses, diluted in serum-free 
DMEM with a M.O.I. of 1.0 was added to the culture. The 2.0 x 105 cells per well was assumed to 
double during incubation so 4.0 x 105 pfu/well of virus was used for an M.O.I. of 1.0.  The virus 
and cells were incubated for 30 minutes at 37 ºC 5% CO2. Then, the virus inoculum was removed, 
and the culture washed one time with 1.0 mL of serum-free media per well. Then, 1.0 mL of 
complete media with the indicated concentration of compound was added to the well, and the 
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infected cells were then incubated for 10 hours at 37 ºC, 5% CO2. After 10 hours the plate was 
stored at -80 ⁰C until the TCID-50 titration. The experiment reported in the Figure 33A was 
repeated independently three times. 
For the compound washout treatment experiments, (Figure 33B), cells were seeded as 
above and a 6 well plate was seeded with 4.5x105 cells per well. After 20 hours of incubation the 
media was gently removed from each well, and 1mL of media was added to each well for the 24 
well plate and 3 mL of media for the 6 well plate with the desired compound concentration to each 
well, without disturbing the cells. Cells were incubated for 6 hours, after which time the media 
was removed and cells were gently washed three times with 1.0 mL of FBS-free DMEM media. 
This was replaced with complete media and cells allowed to incubate for 20 hours, after which 
time the 6 well plate was lysed to quantify OSBP protein levels. After the media was removed, 
CoxA9-01 or Echo2-01 viruses, diluted in serum-free DMEM with a M.O.I. of 1.0 was added to 
the culture. The 2.0 x 105 cells per well was assumed to double and double again during incubation 
so 8.0 x 105 pfu/well of virus was used for an M.O.I. of 1.0.  The virus and cells were incubated 
for 30 minutes at 37 ºC 5% CO2. Then, the virus inoculum was removed, and the culture washed 
one time with 1.0 mL of serum-free media per well. Then, 1.0 mL of complete media was added 
to the well, and the infected cells were then incubated for 10 hours at 37 ºC, 5% CO2. After 10-
hour incubation, the plate was stored at -80 ⁰C until processing. 
Then, the plates were rapidly thawed, the cells in media were scrapped from the wells into 
sterile 1.5 mL centrifuge tubes and the suspension then centrifuged at 10,000 g at 4⁰C to produce 
the virus containing supernatant, which is assayed for TCID-50 titration on sub-confluent RD cells. 
This experiment was performed independently three times to generate the data in the Figure. The 
TCID-50 titration was performed according to the protocol described by Reed et al.(210) The 
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experiment reported in the Figure 33B was repeated independently three times. Viral work was 
performed by Dr. Earl Blewett and analysis of OSBP protein level was done by Mr. Zachary 
Severance. 
4.6.13 Statistical Analysis 
Results are expressed as mean ± s.d. and are n=3 unless otherwise stated. All statistical 
tests were performed using GraphPad Prism 7.0. Comparison between groups were made by using 
a one-way ANOVA with a follow up Dunnett’s test. The p values are reported using GraphPad 

















Chapter 5: Conclusions and Future Outlook 
The work outlined in this dissertation has uncovered a potentially significant cellular effect 
induced by OSW-1 compound treatment that can occur in a variety of cell lines quickly and at 
non-toxic levels. We have shown that ORP4, not only OSBP, is targeted for degradation through 
OSW-1 treatment, which in itself is a new discovery that has implications for the anti-cancer 
avenue of the drug. The degradation of these proteins has a distinct pattern with OSBP being 
degraded to a higher degree and faster than ORP4 in a time dependent manner This finding 
suggests it is possible to preferentially target OSBP over ORP4 with short doses of OSW-1. These 
short doses followed by removal (washouts) lead to multi-day OSBP repression within all human 
cell lines tested, and the viability of washout cells is similar to control cells. The “washout effect” 
can occur in under an hour of treatment at near sub-nanomolar concentrations. We show that 
washout cells have anti-viral activity against two clinical isolates of Enteroviruses, which gives 
rise to the potential of not only a therapy for a virus genus that currently does not have any 
approved treatment, but the potential for a prophylactic therapy. 
The “washout effect” occurs through a currently unidentified cellular mechanism that is 
only caused by OSW-1 treatment and not any other ORPphillin with anti-viral activity. Through 
our experiments we show for the first time that both OSBP and ORP4 are long-lived proteins with 
half-lives of at least 24 hours, and the “washout effect” causes active degradation of OSBP through 
a proteasomal mechanism. This initial degradation by the proteasome does not account for the 
long-term repression of OSBP induced in response to OSW-1 washout treatment. OSW-1 
treatment induces transient autophagy, but OSBP induced reduction by OSW-1 treatment does not 
occur through autophagy-induced proteolysis. We show that the mRNA transcript of OSBP is 
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stable throughout the washout condition and that the global proteome is also largely unaffected as 
a result of these washout conditions. 
Our results also provide insight into other small molecule OSBP inhibitors that have not 
previously had their effects analyzed with respect to OSBP protein levels. We show that of the 
known OSBP inhibitors that have anti-viral activities towards the same viruses as OSW-1, only 
the THEV2 compound binds competitively with a similar Ki. Previous research has showed that 
ITZ and TTP inhibit OSBP sterol/PI4P transport, which is presumably through the LBD, but we 
show that these compounds do not inhibit this function in a competitive manner. There may be an 
alternative binding sites that allow for sterol/PI4P ligands to bind in the LBD but ORPphillin 
binding could inhibit the the transport between membranes. These compounds could also bind in 
a way that prevents sterol binding entirely, more in depth studies need to be performed on ligand 
binding. Regardless of binding ability, none of the compounds besides OSW-1 can induce 
degradation of OSBP, which calls in to question the exact mechanism of the “washout effect”. 
Future work will need to focus on determining the exact repression mechanism by which 
OSW-1 induces OSBP repression for multiple days. As mentioned previously, thapsigargin 
treatment in INS-1E cells appears to have a similar mechanism targeting GRP78. Treatment leads 
to ER stress and repression of GRP78 protein levels that cannot be explained completely through 
proteasomal degradation and overall mRNA levels are increased throughout treatment time(224). 
Similarly, Macrophages treated with deoxynivalenol also lead to degradation of GRP78 protein 
but not mRNA levels, resulting in an ER stress response(225). Prolonged OSW-1 treatment was 
shown to cause degradation of GRP78 through calpain dependent mechanism(130). GRP78 is a 
crucial component of the unfolded protein response (UPR) which is induced under ER stress. ER 
stress was shown to lead to global mRNA stabilization due to the formation of stress granules that 
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can inhibit translation by sequestering mRNA for stabilization or degradation(236). This could be 
a potential mechanism by which OSBP is repressed due to the result of the OSBP mRNA transcript 
being stably expressed throughout the OSW-1 washout recovery period. Prolonged ER stress can 
lead to cell death(237), meaning that the likelihood of ER stress being the sole responsible source 
of repression is unlikely. We have briefly tested the ability of an inhibitor to inositol-requiring 
enzyme 1 (STF-083010)(238), which is involved with ER stress through the UPR, to protect OSBP 
during OSW-1 treatment. The inhibitor failed to rescue OSBP protein levels (Figure 69), which 
provides evidence that OSBP repression goes beyond prolonged ER stress, which is also supported 
by the fact that cells are viable (Figure 21) and the Golgi returns to a normal state during 
washout(Figure 20B). 
Another possible mechanism for prolonged repression is through targeted translational 
repression of the mRNA transcript. Our cycloheximide results show that the half-life of OSBP is 
over 24 hours (Figure 27A) which means the initial degradation is an active process and not due 
to translational inhibition during OSW-1 treatment. Based on the stable OSBP mRNA levels 
throughout the washout, we are unable to rule out that the OSBP mRNA transcript is not being 
translated throughout the recovery process. In order to answer this question, the use of polysome 
profiling with puromycin controls to determine active versus stalled ribosomes(239, 240) could 
determine if the OSBP mRNA transcript in DMSO washout cells is actively being translated 
throughout the entire recovery period, or if the long half-life of OSBP is the result of repression. 
Using the polysome profiling technique(239), we would be able to not only determine the 
translational status of OSBP, but also look at the global translation to see if there are differences 
between the treatments that correspond with our iTRAQ data (Figure 28B & C). 
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If there is a differential pattern in the translation of OSW-1 washout cells, then RNA 
sequencing (RNA-seq), specifically small RNA-seq, could be used to identify differences in the 
transcriptome. It has previously been reported that OSBP and other members of the OSBP/ORP 
family have been targeted by miRNAs(64, 227–229). Identification of miRNA repression through 
RNA-seq could be confirmed by using a target protecting morpholino oligo that binds to the 
mRNA of OSBP to determine if OSBP expression returns. Alternatively, the mRNA transcript 
could be sequestered into p-bodies which can be induced during stress events. In order to determine 
the subcellular localization of the OSBP transcript during washout conditions, using either in situ 
hybridization coupled to immunofluorescence (FISH-IF)(241) or MS2 mRNA-targeting(242) to 
determine where the transcript is located and if it is inside of a p-body. Knowing the exact 
mechanism of OSW-1 induced OSBP repression will advance the potential therapeutic aspect of 
the compound. 
Despite the capacity of the “washout effect”, the fact that OSW-1 is not specific to OSBP 
is concerning. Future research needs to be invested in developing OSW-1 analogs that are 
specific to OSBP which can also induce the “washout effect”. Our results show that there is 
something specific about how OSW-1 binds that induces OSBP degradation. It also seems that 
only specific competitive binding ligands are able to rescue OSBP from this 
degradation(46)(Figure 31 & Figure 32). We have tested the scarce Schweinfurthin A in efforts 
to determine its effect on OSBP protein level during washout conditions and found that it 
induces the “washout effect” but to a much lesser extent and recovers quicker than OSW-1 
(Figure 70). Taken with the results presented earlier, more research needs to be done to 
determine the exact mechanism induced by OSW-1 treatment and what specifically about the 
OSW-1 compound induces the “washout effect”. Regardless of these obstacles, we have 
126 
demonstrated that as of now, OSW-1 treatment for short periods of time is non-toxic and induces 
a prophylactic antiviral response against a genus of viruses that is a public health menace without 
currently approved treatments(243). With the “washout effect” being inducible in all tissues 
types tested so far, and the fact that OSBP is utilized by a plethora of viruses, the application of 
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Appendix 1: Chapter 2 Supplemental 
Figure 34: OSBP and ORP4 Sequence Homology. Protein and DNA Identities and Positives for 
Full length and LBD sequences of OSBP and ORP4. 
Protein Full Length OSBP ORP4
OSBP 77%
ORP4 64%
DNA Full Length OSBP ORP4
OSBP 57.8%
ORP4 57.8%
Protein LBD OSBP ORP4
OSBP 80%
ORP4 68%













Figure 35: Full blots of Figure 17A 
160 
 
Figure 36: Full OSBP blots of Figure 17B. 
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Figure 37: Full ORP4 blots of Figure 17B 
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Figure 39: OSW-1 compound washout shows reduction of OSBP up to 24 hours. Cells were 
treated with 1 nM OSW-1 or DMSO for 6 hours and then the media was replaced and cells were 







Figure 40: Confirmation of OSBP loss by multiple antibodies. A combination of different 
clonalities from various hosts with distinct epitopes shows similar OSBP expression in both 










Figure 42: Continual OSW-1 compound treatment is cytotoxic but OSW-1 compound 
washout cells do not show ORP4 loss similar to OSBP. (A) Calcein AM and Hoechst 33342 
staining of 0-72 hours of 1 nM OSW-1 or DMSO in HEK293 cells using Operetta High-Content 
Imaging System that shows cytotoxicity in OSW-1 treated cells by 24 hours. (B) Western blot 
analysis reveals that ORP4 levels do not experience the same change as OSBP during 1 nM OSW-
1 washout recovery (Full blots in Figure 53). 
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Figure 43: Full blots of  Figure 22A 
168 
 
Figure 44: Full blots of Figure 22B. 
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Figure 45: Full blots of Figure 22C. 
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Figure 46: Sub-nanomolar OSW-1 compound washout treatments lead to significant OSBP 
reduction. 
Cell lines were treated with the indicated concentration of OSW-1 compound for 6 hours and then 
recovered for 24 hours before being analyzed by western blot. Values are mean ± sd (n=3). 
HEK293 results were collected by Mr. Zachary Severance and HCT116 results were collected by 
Mr. Ryan Bensen. (Full western blots in Figure 54) 
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Figure 47: Full Chromatogram of LCMS 100 nM OSW-1 Treatment.  Chromatogram of 
Liquid Chromatography Mass Spectrometry (LCMS) quantification of OSW-1 via an internal 




Figure 48: LCMS Limit of Quantification. 
Spectra of LCMS 100pM OSW-1 spiked lysate sample for limit of quantification. 100pM OSW-1 




Figure 49: Full Chromatogram of SCMS 100 nM OSW-1 Treatment. Chromatogram of Single 
Cell Mass Spectrometry (SCMS) quantification of OSW-1 utilizing a constant flow of d-OSW-1. 
Individual cells were analyzed with the Single-Probe upon detection of the intracellular lipid, 
phosphatidylcholine, and depicted as specified. 
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Figure 50: Spectra of SCMS at 0 and 24 hr Recovery 
Zoomed out spectra of Figure 2 Single Cell Mass Spectrometry (SCMS) detecting 
Phosphatidylserine (PS). PS lipid detection signifies cellular content is being analyzed with either 






Figure 51: Binding curves of OSW-1 to OSBP and ORP4 
Representative binding curves for OSW-1 to overexpressed OSBP and ORP4L in HEK293T cells 
using a competition radioactivity assay against [3H]-25-OHC. Ki values indicated are the average 
between each replicate. The error comprises of standard deviation between the replicates. A 





Figure :  
Figure :  
Figure 52: Full western blots of Figure 40. 
i re 53: Full western blots of Figure 42. (A) HEK293 and (B) HCT116 cells were 
treated with DMSO, 1 nM Taxol, or 1nM OSW-1 for 6 hours followed by compound 
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Figure 55:Full blots of Figure 25. (A) Co-incubation blots correspond to (A) and (B) washout 
blots correspond to (B). 
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Figure 56:Full blots of LC3A/B from Figure 26 
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Figure 57: Full blots of p62 from Figure 26 
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Figure 58:Full OSBP blot from Figure 26 
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Figure 59: Cell splitting and cell density do not recover OSBP. HEK293 cells were treated with 
1nM OSW-1 for 6 hours and then washed out. Following washout cells were split and then diluted 




Figure 60: Full blots of Figure 27 
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Figure 61: OSBP and ORP4 are long lived proteins. (A) OSBP levels in HEK293 and (B) ORP4 
levels in HCT116 show that the half-life of OSBP is over 24 hours. 178 µM Cycoloheximide 
























Figure 63: Full blots from Figure 61. 
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Figure 65: Full blots of Figure 31. 
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Figure 66: THEV2 attenuates OSW-1 induced viability loss. (A) HCT116 cells were treated 
with DMSO, 1 nM OSW-1, or a combination of OSW-1 and 10µM of the indicated compound for 
24 hours after which cell viability was determined by Cell Titer Blue method. (B) HCT116 cells 
were treated with DMSO, 1 nM Taxol, 1 nM OSW-1 or 10µM of the indicated compound for 24 














Figure 67: Co-incubation of OSW-1 and ORPphillins cause variable OSBP localization. 
Indirect immunofluorescence was used to determine localization of OSBP (green) and TGN46 
(red) when incubated with 1 nM OSW-1 and 10 µM of an ORPphillin for 24 hours. Nuclei (blue) 
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Figure 69: An ER-Stress inhibitor does not rescue OSBP induced OSW-1 degradation. 
HEK293 cells were treated with DMSO, 1 nM OSW-1, or 1 nM OSW-1 with 50 µM STF-0803010 




Figure 70: Schweinfurthin A induces OSBP washout, but to a lesser extent than OSW-1.  
Continual 500 nM Schweinfurthin A (SchwA (C), n=1) causes a slight drop of OSBP levels in 
HEK293. 6-hour treatment of 500 nM SchwA followed by washout leads to a significant drop of 
OSBP levels in HEK293 at 0-hour and 24-hour recovery (SchwA (0R) and SchwA (24R), n=3).  
 
 
